Exhibit 10.57
Final Execution Version
DEVELOPMENT AND
COMMERCIALIZATION AGREEMENT
This Development and Commercialization Agreement (this "AGREEMENT") is
made and entered into this 28th day of May, 2004 (the "EFFECTIVE DATE"), by and
between Advancis Pharmaceutical Corporation, a Delaware corporation
("ADVANCIS"), and Par Pharmaceutical, Inc., a Delaware corporation ("PAR").
WHEREAS, Advancis is the owner of certain patents and know-how relating
to formulations for the administration of antibiotics, including its proprietary
PULSYS(TM) technology;
WHEREAS, Advancis has commenced the development of a PULSYS(TM)-based
amoxicillin product; and
WHEREAS, Advancis and Par desire to collaborate in the further
development and commercialization of a PULSYS(TM)-based amoxicillin product.
NOW, THEREFORE, in consideration of the mutual covenants and promises
contained in this Agreement and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, Advancis and Par agree
as follows:
ARTICLE I
DEFINITIONS
The following terms shall have the following meanings:
1.1. "ADULT PRODUCT" means a pharmaceutical presentation of the Compound (a)
that utilizes or incorporates PULSYS(TM), (b) that contains no active
pharmaceutical ingredient (including any active pharmaceutical
ingredient that acts as an [***]) other than the Compound, and (c) that
is used or is being developed for the Adult Product Indication, other
than formulations of Exhibit A.
1.2. "ADULT PRODUCT INDICATION" means [***] in adolescents/adults [***], and
any other indication agreed to by the Parties.
1.3. "ADVANCIS INDEMNIFIED PARTIES" has meaning set forth in Section 13.1.
1.4. "ADVANCIS KNOW-HOW" means Know-How owned by or licensed to Advancis, as
of the Effective Date or owned by or licensed to Advancis after the
Effective Date, which Know-How relates to, underlies or arises out of
Advancis's proprietary technology that is used in the development,
manufacture, use or sale of Product.
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
1
- --------------------------------------------------------------------------------
1.5. "ADVANCIS PATENT RIGHTS" means all Patent Rights owned by or licensed
to Advancis as of the Effective Date or owned by or licensed to
Advancis after the Effective Date, which Patent Rights relate to,
underlie or arise out of Advancis's proprietary technology and that are
required or utilized for manufacture, use, or sale of Product.
1.6. "ADVANCIS SLOGAN" has the meaning set forth in Section 5.4.1.
1.7. "AFFILIATE" means any Person that directly or indirectly Controls, is
Controlled by or is under common Control with either Par or Advancis,
as applicable. For purposes of this definition, "CONTROL" means the
power to direct or cause the direction of the management and policies
of a Person, whether pursuant to the ownership of voting securities, by
contract or otherwise.
1.8. "ALLIANCE MANAGER" has the meaning set forth in Section 3.1.4.
1.9. "BASEBALL ARBITRATION" has the meaning set forth in Section 17.2.2.
1.10 "BASEBALL ARBITRATION NOTICE" has the meaning set forth in Section
17.2.2.
1.11 "CGMP" means the regulatory requirements for current good manufacturing
practices promulgated by the FDA under the U.S. Food, Drug and Cosmetic
Act and the regulations promulgated thereunder, particularly 21 C.F.R.
Section 210 et seq., and 21 C.F.R. Sections 600-610, as the same may be
amended from time to time.
1.12 "CLINICAL SUPPLIES" means supplies of Products, manufactured, packaged
and labeled in compliance with cGMP, in such form and dosage as is
determined by Advancis pursuant to the Development Plan, and suitable
for use in the conduct of pre-clinical and/or human clinical trials of
the Products in the United States by the Parties pursuant to the
Development Plan.
1.13 "COLLABORATION PAYMENTS" has the meaning set forth in Section 6.2.
1.14 "COMMERCIALIZATION" means the marketing, promotion, advertising,
selling and/or distribution of Products in the United States after
Regulatory Approval has been obtained. The term "COMMERCIALIZE" has a
corresponding meaning.
1.15 "COMMERCIALIZATION PLAN" has the meaning set forth in Section 5.2.1.
1.16 "COMMERCIALIZATION PROGRAM" means the Commercialization program
conceived, planned, organized, and performed by the Parties for the
purpose of bringing the Products to market for sale in the United
States, in accordance with the Commercialization Plan.
1.17 [***]
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
2
- --------------------------------------------------------------------------------
1.18 "COMMERCIAL SUPPLIES" means supplies of Product, manufactured, packaged
and labeled in compliance with cGMP, in such form and dosage as is
determined by Advancis pursuant to the Development Plan, and suitable
for Commercialization in the United States by the Parties pursuant to
the terms of this Agreement and the annual Commercialization Plans. As
used herein, "Commercial Supplies" includes Samples.
1.19 "COMMERCIALIZATION PARAMETERS AND DETAILING SCHEDULE" means the
schedule, attached to this Agreement as Exhibit C, that addresses the
Detailing and Promotional activities for each Party during the Term.
The objectives of Exhibit C automatically shall be incorporated in and
be part of the initial Commercialization Plan upon approval of the
initial Commercialization Plan, and may be amended solely in
conjunction with the amendment of the initial Commercialization Plan.
1.20 "COMPOUND" means the compound amoxicillin, including all racemates,
chelates, complexes, enantiomers, diastereoisomers, salts, bases,
esters, hydrates, solvates, polymorphs, crystal forms, crystal habits,
prodrugs, isotopic or radiolabeled equivalents, metabolites, or the
like, thereof and all mixtures of any of the foregoing.
1.21 "CONFIDENTIAL INFORMATION" means information of a Party that is
disclosed to or obtained by the other Party (including information
obtained by a Party as a result of access to the facilities of the
other Party) either prior to or during the term of this Agreement which
information (a) is non-public, confidential or proprietary in nature,
including trade secrets, financial data, product information,
manufacturing methods, market research data, marketing plans, identity
of customers, nature and source of raw materials, product formulation
and methods of producing, testing and packaging, and (b) relates to the
disclosing Party's past, present or future research, development or
Commercialization activities; provided, however, that Confidential
Information shall not include information that a Party can demonstrate
by written evidence: (i) is in the public domain other than as a result
of a breach by such Party (or any of its Affiliates) of its obligations
of confidentiality contained herein; (ii) was known by the receiving
Party prior to receipt from the disclosing Party; (iii) has been
developed by the receiving Party independent of any Confidential
Information of the other Party; or (iv) was subsequently, lawfully and
in good faith obtained by the receiving Party on a non-confidential
basis from a third party that was not under an obligation to treat such
information in a confidential manner and had a lawful right to make
such disclosure. Without limiting the foregoing, the terms of this
Agreement, including the Development Plan and each Commercialization
Plan, shall constitute "Confidential Information" hereunder.
1.22 "DAMAGES" has the meaning set forth in Section 11.2.3.
1.23 "DEFAULTING PARTY" has the meaning set forth in Section 12.2.1.
3
- --------------------------------------------------------------------------------
1.24 "DETAIL" has the meaning set forth in Exhibit C.
1.25 "DETAILING PRIORITIES" has the meaning set forth in Exhibit C.
1.26 "DETAILING REQUIREMENTS" has the meaning set forth in Exhibit C.
1.27 "DEVELOPMENT AND MANUFACTURING SUBCOMMITTEE" has the meaning set forth
in Section 3.3.
1.28 "DEVELOPMENT COSTS" has the meaning set forth Exhibit B.
1.29 "DEVELOPMENT FUNDING GAP" means the excess of (a) the aggregate amount
of Development Costs incurred by Advancis from the Effective Date over
(b) the aggregate amount of the installment payments made by Par after
the Effective Date pursuant to Section B.10 of Exhibit B.
1.30 "DEVELOPMENT PLAN" means the plan for the implementation and funding of
the Development Program mutually agreed to by the Parties, which plan
is designed to generate the development, clinical and regulatory
information required for filing NDAs and to further support the
development of Products for the purpose of obtaining Regulatory
Approvals, and any revisions thereto that are made in accordance with
this Agreement.
1.31 "DEVELOPMENT PROGRAM" means the research and development program
conceived, planned, organized, controlled and performed by Advancis to
develop the Products for Commercialization, in accordance with the
Development Plan. The Development Program includes all activities
related to Product Studies, toxicology, formulation, process
development, quality assurance/quality control, and regulatory affairs
for a Product in connection with obtaining Regulatory Approvals of such
Product.
1.32 "DRAFT PLAN" has the meaning set forth in Section 5.2.1.
1.33 "EFFECTIVE DATE" has the meaning set forth in the preamble.
1.34 "FDA" means The Food and Drug Administration of the United States
Department of Health and Human Services, or any successor agency(ies)
thereof performing similar functions.
1.35 "FINANCIAL PLANNING SCHEDULE" means the financial planning, accounting
and reporting schedule of the Parties relating to the costs, budgeting,
funding, and related financial and accounting matters relevant to this
Agreement, a copy of which is attached to this Agreement as Exhibit B.
1.36 "FTE" has the meaning set forth in Exhibit B.
1.37 "FTE RATE" has the meaning set forth in Exhibit B.
4
- --------------------------------------------------------------------------------
1.38 "INDEMNITOR" has the meaning set forth in Section 13.3.
1.39 "INDEMNITEE" has the meaning set forth in Section 13.3.
1.40 "INDICATIONS" means the Adult Product Indication and the Pediatric
Product Indications.
1.41 "INVENTION" means any invention or discovery, whether patentable or
unpatentable, made or discovered while performing under this Agreement.
1.42 "INVOICE" has the meaning set forth in Exhibit B.
1.43 "FINANCE SUBCOMMITTEE" has the meaning set forth in Section 3.5.
1.44 "KNOW-HOW" means all data, experience, inventions, discussions, trade
secrets, compositions of matter and methods, procedures, processes,
materials, know-how or other scientific or technical information of any
kind of a Party, whether existing prior to or during the term of this
Agreement, and whether or not patentable or confidential, including
biological, chemical, biochemical, toxicological, pharmacological,
metabolic, formulation, clinical, analytical, and stability information
and data.
1.45 "LOSSES" has the meaning set forth in Section 13.1.
1.46 "MANUFACTURING COSTS" has the meaning set forth in Exhibit B.
1.47 "MARKETING DISTRIBUTORS" means a Third Party to whom Par or its
Affiliate has granted a right to distribute Products.
1.48 "NDA" means a New Drug Application as defined in the United States
Federal Food, Drug and Cosmetic Act and applicable regulations
promulgated thereunder as amended from time to time.
1.49 "NET SALES OF PRODUCTS" has the meaning set forth in Exhibit B.
1.50 "NON-DEFAULTING PARTY" has the meaning set forth in Section 12.2.1.
1.51 "OFFICE OF NEW DRUGS" means the Office of New Drugs within the Office
of the Center Director of the FDA's Center for Drug Evaluation and
Research.
1.52 "OPERATING PROFITS" has the meaning set forth in Exhibit B.
1.53 "OPTION" has the meaning set forth in Section 2.2.
1.54 "OPTION CANDIDATE" has the meaning set forth in Section 2.2.
1.55 "PAR INDEMNIFIED PARTIES" has meaning set forth in Section 13.2.
1.56 "PARTY" or "PARTIES" means Advancis and/or Par, as applicable.
5
- --------------------------------------------------------------------------------
1.57 "PATENT RIGHTS" means any of the following: (a) United States patents;
(b) United States patent applications (both provisional and
non-provisional), PCT patent applications, and divisionals,
continuations and claims of continuation-in-part applications which
shall be directed to subject matter specifically described in such
United States and/or PCT patent applications, and the resulting patents
(whether such divisionals, continuations or continuation-in-part
applications are based upon a United States patent, United States
patent application or PCT application); (c) any patents resulting from
reissues or reexaminations of the United States patents described in
(a) and (b) above; (d) foreign patents; (e) foreign patent applications
and, to the extent applicable, divisionals, continuations and claims of
continuation-in-part applications which shall be directed to subject
matter specifically described in such foreign patent applications, and
the resulting patents (whether such divisionals, continuations or
continuation-in-part applications are based upon a foreign patent
application or a foreign patent); and (f) any foreign patents,
resulting from foreign procedures similar to United States reissues and
reexaminations, of the foreign patents and applications described in
(d) and (e) above.
1.58 "PDMA" means the Prescription Drug Marketing Act of 1987.
1.59 "PEDIATRIC PRODUCT" means the pharmaceutical presentation of the
Compound (a) that utilizes or incorporates PULSYS(TM), (b) that
contains no active pharmaceutical ingredient (including any active
pharmaceutical ingredient that acts as a [***]) other than the
Compound, and (c) that is used or is being developed for the Pediatric
Product Indications, other than formulations of Exhibit A.
1.60 "PEDIATRIC PRODUCT INDICATIONS" means (i) [***] (proposed Phase III
Studies protocol 231.301); (ii) [***]; and (c) any other indications
agreed to by the Parties.
1.61 "PERSON" means an individual, partnership, joint venture, association,
corporation, limited liability company and any other form of business
organization, government, regulatory or governmental agency,
commission, department or instrumentality.
1.62 "PHASE III STUDY(IES)" means that portion of the Development Program
that provides for large scale, pivotal, clinical studies that (a) are
conducted in a number of patients that is intended to be sufficient to
obtain a definitive evaluation of the therapeutic efficacy and safety
of a Product in patients for a given Indication and (b) that are needed
to evaluate the overall risk-benefit relationship of the Products and
to provide adequate basis for obtaining requisite Regulatory Approvals.
1.63 "PRELIMINARY COMMERCIALIZATION PLAN" means the Commercialization Plan
presented to Par by Advancis on April 14, 2004.
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
6
- --------------------------------------------------------------------------------
1.64 "PREMARKETING COSTS" has the meaning set forth in Exhibit B.
1.65 "PREMARKETING PROGRAM" means the program to be conceived, planned,
organized and performed by the Parties from and after the Effective
Date for the purpose of bringing the Products to market for sale in the
United States after Regulatory Approval for such sale has been
obtained, as set forth in the Commercialization Plan.
1.66 "PRINCIPAL TRADEMARK" has the meaning set forth in Section 5.4.1.
1.67 "PRODUCT INFRINGEMENT" has the meaning set forth in Section 11.2.3.
1.68 "PRODUCTS" means the Adult Product and the Pediatric Product.
1.69 "PRODUCT SALES FORCE" has the meaning set forth in Exhibit C.
1.70 "PRODUCT SALES FORCE COSTS" has the meaning set forth in Exhibit B.
1.71 "PRODUCT STUDIES" means clinical studies, pre-clinical studies, safety
studies, epidemiological studies, modeling and pharmacoeconomic
studies, in each case including any ancillary or incidental
development, investigation or research schemes pertaining thereto, that
are designed (a) to support Regulatory Approval for the Products or (b)
to support publications, Promotional and educational activities, future
labeling changes or new Indications for the Products.
1.72 "PRODUCT TRADEMARKS" has the meaning set forth in Section 5.4.1.
1.73 "PROGRAM DEVELOPMENTS" means all Inventions, discoveries, Patent
Rights, Know-How, copyrights and works of authorship that are made,
developed, created, conceived or reduced to practice in connection with
or relating to the Development Program or Commercialization Program
during the term of this Agreement, regardless of whether the Invention,
discovery, Know-How, or work is patentable and regardless of whether it
was made solely by an employee or agent of Par, solely by an employee
or agent of Advancis, or jointly by Par and Advancis.
1.74 "PROMOTE" has the meaning set forth Exhibit C. The term "PROMOTIONAL"
has a corresponding meaning.
1.75 "PROMOTION COSTS" has the meaning set forth in Exhibit B.
1.76 "PROMOTIONAL MATERIALS" has the meaning set forth in Section 5.2.4.1.
1.77 "PROPOSAL" has the meaning set forth in Section 17.2.2.
1.78 "PROPOSED PHASE III PROTOCOLS" means, collectively, Advancis's current
proposals for Phase III Studies protocols for the Products with respect
to the Indications.
7
- --------------------------------------------------------------------------------
1.79 "PULSYS(TM)" means drug delivery technology involving front-loaded,
sequential bursts, or pulses, of a pharmaceutical product.
1.80 "RECALL" has the meaning set forth in Section 16.1.
1.81 "REGULATORY APPROVAL" means approval by the FDA to market the Products
in the United States, including the issuance by the FDA of an action
letter indicating that an NDA is approved, final FDA approval of
Promotional materials for Products sufficient for launch, and final FDA
approval of manufacturing processes and facilities for Products
sufficient that Commercial Supplies of Products can be manufactured
prior to launch.
1.82 "REPRESENTATIVES" has the meaning set forth in Section 10.1 below.
1.83 "SALES AND MARKETING SUBCOMMITTEE" has the meaning set forth in Section
3.4.
1.84 "SALES REPRESENTATIVES" has the meaning set forth in Exhibit C.
1.85 "SAMPLE" means a Product packaged and distributed to a Target
Prescriber as a complementary trial for use with patients in the United
States and in accordance with the PDMA.
1.86 "SECTION 4.2.2.2 PERIOD" has the meaning set forth in Section 4.2.2.2.
1.87 "SECTION 4.2.2.3 AMOUNT" has the meaning set forth in Section 4.2.2.3.
1.88 "SUBCOMMITTEE" has the meaning set forth in Section 3.1.5.
1.89 "SUPPLY AGREEMENT" has the meaning set forth in Section 8.3.
1.90 "TARGETED PRESCRIBERS" has the meaning set forth in Exhibit C.
1.91 "TERM" has the meaning set forth in Section 12.1 below.
1.92 "THIRD PARTY" means any party other than Par, Advancis and their
respective Affiliates.
1.93 "TERRITORY" means [***], subject to the provisions of Exhibit D.
1.94 "TOTAL DETAILS" means the aggregate number of Details and the Detail
Priorities therefor for the applicable calendar year as set forth in
the Commercialization Plan for the applicable calendar year.
1.95 "VALID CLAIM" means either (a) a claim contained in an issued and
unexpired patent which constitutes Advancis Patent Rights which claim
(i) has not been held unenforceable, unpatentable or invalid by a
governmental agency or a court of competent jurisdiction in a decision
which is unappealable or which was not appealed within the time allowed
for appeal, and (ii) has not been admitted to be unenforceable,
unpatentable or invalid through abandonment, reissue, disclaimer
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
8
- --------------------------------------------------------------------------------
or otherwise, or (b) a claim contained in a pending patent application
which constitutes Advancis Patent Rights which claim (i) has not been
abandoned or finally rejected by Advancis without the possibility of
appeal or re-filing and (ii) has been under examination for less than
four (4) years.
ARTICLE II
SCOPE OF THE COLLABORATION
2.1 PRODUCTS. The Parties agree, pursuant and subject to the terms of
this Agreement, that the goals of their collaboration under this Agreement are
to develop the Products to obtain Regulatory Approval for such Products in the
Territory in commercially-significant indications and to Commercialize such
Products in the Territory as soon as reasonably practicable. Except as otherwise
expressly provided herein, each Party shall use Commercially Reasonable Efforts
to perform its tasks and obligations under this Agreement, including under the
Development Plan and each Commercialization Plan, and each Party shall cooperate
with the other Party in the performance of such other Party's tasks and
obligations hereunder.
2.2 OPTION. (a) During the Term, [***]; and Advancis agrees to [***] to
[***]. Advancis shall provide Par with written notice of the Option Candidate
and provide Par information reasonably available to Advancis, including an
estimate of the cost for developing and obtaining regulatory approval therefor
that is reasonably required by Par to make a determination as to whether or not
to enter into an agreement with Advancis with respect to such Option Candidate.
The delivery of such notice shall automatically grant to Par an exclusive Option
to enter into an agreement with Advancis with respect to such Option Candidate
(the "Option"). Within [***] after Par's receipt of notification of the Option
Candidate from Advancis, Par shall have the right to (a) exercise the Option by
delivering to Advancis a written notice of exercise; or (b) reject the Option.
If Par fails to exercise the Option within [***] after Par's receipt of
notification of the Option Candidate from Advancis, the Option shall be deemed
rejected and shall expire. If Par exercises the Option, Advancis shall negotiate
exclusively and in good faith with Par the terms of a development and
commercialization agreement for the Option Candidate for a period of [***]
following exercise of the Option (the "Candidate Agreement"). The Candidate
Agreement shall be on terms substantially similar to those of this Agreement and
shall include the following terms: (i) Advancis is the Selling Party and Par
shall co-promote, with each Party having the right to perform [***] of the
details and neither Party shall be required to perform more than [***] of the
details and neither party shall perform less than forty percent of the details,
(ii) the Parties shall [***], (iii) the Parties shall [***], (iv) each Party
shall [***], (v) Par shall [***], and (vi) Par shall [***].
If at the end of the [***], the Parties have not reached agreement as
to all of the terms and conditions of the Candidate Agreement, then at any time
thereafter either Party shall have the right to submit to Baseball Arbitration
the terms and conditions as to which agreement has not been reached. It is
expressly understood and agreed that the terms that have been set forth in
Section 2.2(i)-(vi) shall be included in the Candidate Agreement and such terms
may not be varied or changed by the Baseball Arbitration.
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
9
- --------------------------------------------------------------------------------
(b) If an Option is rejected by Par pursuant to Section 2.2(a) with
respect to an Option Candidate, then Advancis agrees to offer Par one other
Option Candidate pursuant to Section 2.2(a). It is expressly understood that
this Section 2.2(b) applies only once.
2.3 NON-COMPETITION. During the Term, and except as through the
Collaboration pursuant to this Agreement neither party for the Territory shall
develop, market, sell or distribute any pharmaceutical product that [***],
wherein the sole active pharmaceutical ingredient in such product is the
compound amoxicillin, including chelates, complexes, hydrates, solvates,
polymorphs or other crystal forms or habits, or radiolabled equivalents or any
mixture of the foregoing. Notwithstanding the foregoing, it is expressly agreed
that this Section 2.3 does not apply to any formulations of Exhibit A.
ARTICLE III
MANAGEMENT OF THE COLLABORATION
3.1 EXECUTIVE COMMITTEE.
3.1.1. ESTABLISHMENT. The Parties hereby establish an Executive
Committee consisting of six (6) members, three (3) of whom shall be Par
designees and three (3) of whom shall be Advancis designees. Each of the
Executive Committee members shall have appropriate expertise to oversee the
Parties' performance of this Agreement and at least two (2) designees of each
Party must have the rank of Vice President or higher within such Party;
provided, that neither Party shall designate its chief executive officer to
serve on the Executive Committee. The initial Executive Committee members shall
be designated by each Party within one week of the Effective Date. Each Party
shall have the right at any time and from time to time to designate a
replacement, on a permanent or temporary basis, for any or all of its
previously-designated members of the Executive Committee. At the beginning of
each calendar year during the Term, each Party shall appoint one of its
designees to serve as a Co-Chair of the Executive Committee. The initial
Co-Chairs shall be designated by each Party within one week of the Effective
Date.
3.1.2. MEETINGS AND PROCEDURES.
3.1.2.1 The Executive Committee shall meet at least once per
calendar quarter, and more frequently at the request of either Party or as
required to resolve disputes, disagreements or deadlocks, on such dates, and at
such places and times, as the Parties shall agree; provided that the Parties
shall use their Commercially Reasonable Efforts to cause the first meeting of
the Executive Committee to occur within thirty (30) days after the Effective
Date. The two Co-Chairs shall cooperate to send a notice and agenda for each
meeting of the Executive Committee to all members of the Executive Committee
reasonably in advance of the meeting. The location of regularly-scheduled
Executive Committee meetings shall alternate between the offices of the Parties,
unless otherwise agreed. The members of the Executive Committee also may convene
or be polled or consulted from time to time by means of telephone conference,
video conference, electronic mail or correspondence and the like, as deemed
necessary or appropriate by the Co-Chairs. The Party hosting any Executive
Committee meeting shall appoint one person (who need not be a member of the
Executive Committee) to attend the meeting and record the minutes of the meeting
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
10
- --------------------------------------------------------------------------------
in writing. Such minutes shall be circulated to the members of the Executive
Committee promptly following the meeting for
review and comment.
3.1.2.2 All decisions of the Executive Committee shall be
made by unanimous vote or unanimous written consent of both Parties, with each
Party having, collectively, among its respective designees, one vote in all
decisions. The members of the Executive Committee shall use Commercially
Reasonable Efforts to decide all matters assigned to the Executive Committee
under this Agreement or otherwise referred to it by mutual agreement of the
Parties. Any matter that is not decided shall be subject to resolution by the
chief executive officers of the Parties pursuant to Section 17.1 and,
thereafter, by arbitration in accordance with Section 17.2.2.
3.1.3. PURPOSES AND POWERS. The principal purpose of the
Executive Committee shall be to approve the overall strategy for the Parties'
collaboration hereunder and provide guidance and direction as provided herein.
Subject to the express rights of the Parties as set forth herein, the functions
of the Executive Committee shall include:
3.1.3.1 Acting as liaison between the Parties to ensure that
they are informed of the ongoing progress of the Development Program and the
Premarketing Program;
3.1.3.2 Reviewing and approving the division of
responsibilities between the Parties as set forth herein and as expanded from
time to time in furtherance of the goals of the Parties' collaboration;
3.1.3.3 Reviewing and approving any proposed amendments to
the Commercialization Plans and, reviewing proposed amendments to the
Development Plan;
3.1.3.4 Establishing and empowering Subcommittees and
overseeing their work on an ongoing basis;
3.1.3.5 Reviewing and approving the work of the Finance
Subcommittee on all financial aspects of the Commercialization Plans and with
respect to the Development Plan review only on an ongoing basis, including
funding requirements, budget comparisons, expense levels and financial results;
3.1.3.6 Reviewing and approving activities related to
manufacturing of the Products and the selection of manufacturer(s) for the
Products;
3.1.3.7 Reviewing and approving annual marketing and sales
budgets for the Products based on the then-current Commercialization Plan, and
determining any Phase IV clinical support to be provided by the Parties
(including scope and strategic direction);
3.1.3.8 In accordance with the procedures established below,
resolving disputes, disagreements and deadlocks between the Parties;
3.1.3.9 Performing such other responsibilities as may be
assigned to the Executive Committee pursuant to this Agreement or as may be
mutually agreed upon by the Parties from time to time.
11
- --------------------------------------------------------------------------------
3.1.3.10 Reviewing and final approval of each Draft Plan
and/or revisions and/or amendments thereto and any amendments to any
Commercialization Plan.
3.1.4. ALLIANCE MANAGERS. The Co-Chair appointed by each Party
will designate another person representing the same Party who has a general
understanding of clinical, regulatory, commercial and manufacturing issues to
act as the Alliance Manager for such Party (each, an "ALLIANCE MANAGER"). The
role of the Alliance Managers shall be to serve as a single point of contact
within each Party to facilitate communication, collaboration and dispute
resolution between the Parties. The Alliance Managers shall have access to the
decision-makers within their respective Parties and shall have the right to
attend (but not to vote at) all meetings of the Subcommittees. The Co-Chairs
shall inform the Alliance Managers of potential or pending disagreements and key
decisions. The Alliance Managers shall work together to resolve issues and
potential disputes with a view to enabling the Executive Committee and the
Subcommittees to reach unanimous decisions and to avoiding escalation of such
matters.
3.1.5. SUBCOMMITTEES. In addition to the Development and
Manufacturing Subcommittee, the Sales and Marketing Subcommittee and the Finance
Subcommittee (as defined below), the Executive Committee may from time to time,
in its sole discretion, create one or more joint subcommittees (each, a
"SUBCOMMITTEE"), each to consist of an equal number of designees of each Party,
for the purpose of implementing directives of the Executive Committee and
strategies and programs that support and implement the Development Program, the
Commercialization Program and the Premarketing Program. Such Subcommittees shall
meet at such times and locations and shall otherwise be governed by and subject
to such rules, processes and procedures as shall be approved by the Executive
Committee. Except as expressly provided herein or in a written delegation of
authority by the Executive Committee, no Subcommittee shall have the right to
exercise any decision-making authority of the Executive Committee.
3.1.6. EXPENSES. Each Party shall bear the cost of travel and
other expenses relating to the attendance of its designees at all meetings of
the Executive Committee and all Subcommittee(s).
3.1.7. NONDISCLOSURE AGREEMENT. All designees of each Party
serving on the Executive Committee and any Subcommittee(s) shall as a condition
to such service execute a nondisclosure and assignment of inventions agreement
in form and substance reasonably satisfactory to the Parties.
3.2 DEVELOPMENT AND MANUFACTURING SUBCOMMITTEE. Within thirty (30) days
after the Effective Date, the Parties shall establish a Subcommittee (the
"DEVELOPMENT AND MANUFACTURING SUBCOMMITTEE") with responsibility for (a)
overseeing the manufacture of all Products and all Compound used therein, (b)
reviewing proposed additions to the Development Plan for presentation to the
Executive Committee (other than budgetary, expense, and other financial matters,
which shall be presented by the Finance Subcommittee); (c) reviewing proposed
changes to the Development Plan and receiving updates regarding Advancis's
execution of the Development Program; (d) recommending the priority and design
of clinical trials for new Indications and formulations; (e) recommending the
priority of actions to be taken with respect to seeking Regulatory Approval for
the Products; (f) reviewing third party manufacturing and supply agreements with
12
- --------------------------------------------------------------------------------
respect to the Products; (g) assisting to identify responses to potential
interruptions in the supply of Compound or Products; (h) supervising audits of
any third party suppliers of Compound or Products; (i) supervising
implementation of improvements in quality control and assurance, cost reduction
initiatives, logistics initiatives, environmental, health and safety initiatives
and similar programs; and (j) performing such other duties as may be assigned
under this Agreement or as may be delegated to the Development and Manufacturing
Subcommittee by the Executive Committee; provided, that nothing in this Section
3.3 shall limit the rights or obligations of the Parties under Articles IV and
VIII or under the Supply Agreement. Each Party shall appoint two designees to
the Development and Manufacturing Subcommittee each of whom shall have expertise
and experience in the areas of pharmaceutical development and manufacturing.
Either Party may replace any or all of its designees on the Development and
Manufacturing Subcommittee at any time upon written notice to the other Party,
and any member of the Development and Manufacturing Subcommittee may designate a
suitable proxy to perform the functions of that member at any time. In addition,
the Development and Manufacturing Subcommittee shall seek to act with the
unanimous consent of all members of the Development and Manufacturing
Subcommittee. In the event that the Development and Manufacturing Subcommittee
members do not reach consensus with respect to a matter that is within the
purview of the Development and Manufacturing Subcommittee, the Development and
Manufacturing Subcommittee designees of each Party shall collectively have one
vote for purposes of decision-making hereunder with respect to such matters,
with decisions made by unanimous vote of both Parties. If the votes of the
Development and Manufacturing Subcommittee are split on any matter, such matter
shall be referred to the Executive Committee for decision.
3.3 SALES AND MARKETING SUBCOMMITTEE. Within thirty (30) days after the
Effective Date, the Parties shall establish a Subcommittee (the "SALES AND
MARKETING SUBCOMMITTEE") with responsibility for (a) preparing Draft Plans for
each calendar year and, in conjunction with the Finance Subcommittee, annual
budgets; (b) monitoring compliance with and implementation of the then-current
Commercialization Plan; (c) formulating proposed additions or revisions to the
then-current Commercialization Plan for presentation to the Executive Committee
(other than budgetary, expense, and other financial matters, which shall be
presented by the Finance Subcommittee); (d) developing a life cycle management
plan in conjunction with the Development and Manufacturing Subcommittee, (e)
developing and discussing strategies for the promotion and marketing of Products
in the United States, including allocation of responsibility for marketing and
commercialization activities; (f) identifying publication strategies and
scheduling participation in key scientific and clinical meetings and similar
events for the Products (g) determining the launch dates for the Products, (h)
determining the prices for the Products and any of discounts that may be offered
by the Parties, (i) preparing short- and long-term sales forecasts, (j)
presenting forecasts and results of all Commercialization efforts in the
Territory to the Executive Committee as needed but not less than once per
quarter, (k) overseeing all Recalls, market withdrawals and other corrective
actions related to the Products in the Territory, (l) developing positioning and
marketing strategies consistent with the then-current Commercialization Plan,
including any decision to seek or include any new Indications for the Products,
(m) developing advertising and promotional materials for use by the Product
Sales Force, (n) planning and overseeing medical education programs, (o)
developing and implementing a publication or data dissemination strategy, (p)
creating product presentations and exhibits for major medical meetings, (q)
scheduling joint meetings of the Product Sales Force, (r) overseeing and
13
- --------------------------------------------------------------------------------
implementing Phase IV programs, (s) reviewing and adjusting Targeted Prescriber
lists, (t) delegating responsibility for interacting with advertising agencies
and medical education agencies and (u) performing such other duties as may be
assigned under this Agreement or as may be delegated to the Sales and Marketing
Subcommittee by the Executive Committee; provided, that nothing in this Section
3.3 shall limit the rights or obligations of the Parties in this Agreement. Each
Party shall appoint three designees to the Sales and Marketing Subcommittee,
each of whom shall have expertise and experience in the areas of marketing,
promotion, advertising and sales. Either Party may replace any or all of its
designees on the Sales and Marketing Subcommittee at any time upon written
notice to the other Party, and any member of the Sales and Marketing
Subcommittee may designate a suitable proxy to perform the functions of that
member at any time. In addition, the Sales and Marketing Subcommittee shall seek
to act with the unanimous consent of the members of the Sales and Marketing
Subcommittee. In the event that all of the Sales and Marketing Subcommittee
members do not reach consensus with respect to a matter that is within the
purview of the Sales and Marketing Subcommittee, the Sales and Marketing
Subcommittee designees of each Party shall collectively have one vote for
purposes of decision-making hereunder with respect to such matters, with
decisions made by unanimous vote of both Parties. If the votes of the Sales and
Marketing Subcommittee are split on any matter, such matter shall be referred
(by way of the Alliance Managers) to the Executive Committee for decision.
3.4 FINANCE SUBCOMMITTEE. Within thirty (30) days after the Effective
Date, the Parties shall establish a Subcommittee (the "FINANCE SUBCOMMITTEE")
with responsibility for administering all financial, budgetary and accounting
matters that arise in connection with Development Program, the Commercialization
Program and the Premarketing Program and performing such other duties as may be
assigned under this Agreement or as may be delegated to the Finance Subcommittee
by the Executive Committee; provided, that nothing in this Section 3.4 shall
limit the rights or obligations of the Parties in this Agreement. Each Party
shall appoint a senior financial manager and one other designee to the Finance
Subcommittee, each of whom shall have expertise in the areas of accounting, cost
allocation, budgeting and financial reporting. Either Party may replace any or
all of its designees on the Finance Subcommittee at any time upon written notice
to the other Party, and any member of the Finance Subcommittee may designate a
suitable proxy to perform the functions of that member at any time. In addition,
the Finance Subcommittee shall seek to act with the unanimous consent of all
members of the Finance Subcommittee. In the event that the Finance Subcommittee
members do not reach consensus with respect to a matter that is within the
purview of the Finance Subcommittee, the Finance Subcommittee designees of each
Party shall collectively have one vote for purposes of decision-making hereunder
with respect to such matters, with decisions made by unanimous vote of both
Parties. If the votes of the Finance Subcommittee are split on any matter, such
matter shall be referred (by way of the Alliance Managers) to the Executive
Committee for decision.
3.5 SPECIFIC PROVISIONS CONTROL. Nothing in this Article III shall
apply to or limit in any way the decisions made by a Party with respect to
matters for which any other provision of this Agreement expressly grants such
Party sole decision-making authority.
3.6 The committees and subcommittees cannot make any decision that
amends the terms and conditions of this Agreement or that changes the rights and
obligations of the Parties under this Agreement.
14
- --------------------------------------------------------------------------------
ARTICLE IV
DEVELOPMENT PROGRAM
4.1 ADVANCIS RESPONSIBILITY AND CONTROL. Within one week of the
Effective Date the Parties shall mutually agree in writing upon a Development
Plan. Subject to the Development Plan and the other terms and conditions
contained in this Agreement, Advancis shall have the sole control and
responsibility for executing the Development Program, including planning,
strategy, administrative management, overall fiscal control and execution of the
Development Program. The Development Program shall be conducted at and
coordinated from the facilities of Advancis. Advancis shall keep Par apprised of
the status of the Development Program through the Development and Manufacturing
Subcommittee and, as appropriate, the Executive Committee. Advancis shall
comply, and shall require all of its third party agents and contractors, if any,
to comply, with all applicable laws in the conduct of the Development Program.
4.2 DEVELOPMENT PLAN.
4.2.1 CONDUCT BY ADVANCIS. Advancis shall [***] to conduct the
Development Program in accordance with the Development Plan. Notwithstanding the
foregoing or any other provision of this Agreement, Par acknowledges and agrees
that (a) the Development Program is experimental in nature; (b) Advancis does
not guaranty that the Development Program will be successful or that Regulatory
Approval will be obtained for any Product and (c) except for a failure of
Advancis to [***], Advancis will have no liability to Par as a result of any
failure to achieve or delay in achieving the Development Plan, or any milestones
therein, nor shall Advancis have any liability to Par as a result of any failure
to obtain or delay in obtaining Regulatory Approval.
4.2.2 REVISIONS TO DEVELOPMENT PLAN.
4.2.2.1 During the Term, Advancis may revise the Development
Plan at any time and from time to time in its discretion upon notice to Par in
response to developments during the Term, including with respect to the status
of clinical trials, Regulatory Approval efforts, financial matters, and the
like; provided that Par shall have [***] after receiving any proposed material
revisions (including any revisions reasonably likely to adversely affect the
budgets, timeline, Product profile or development strategy of the Products) from
Advancis in which to request in writing that the revised Development Plan be
submitted for the review of the Development and Manufacturing Subcommittee. If
Par does not provide a written request for review by the Development and
Manufacturing Subcommittee to Advancis within such [***], then the proposed
Development Plan shall be deemed accepted by Par. If Par does request in writing
that the Development and Manufacturing Subcommittee review the proposed
Development Plan within such [***], then Par and Advancis shall promptly convene
a meeting of the Development and Manufacturing Subcommittee to review and
approve such proposed Development Plan in accordance with Section 3.2, subject
to (a) referral of such matter to the Executive Committee, if the Development
and Manufacturing Subcommittee fails to reach a decision and (b) submission of
such matter to the chief executives of the parties in accordance with Section
17.1 if the Executive Committee fails to reach a decision, if the chief
executives fail to reach a decision in [***], the then proposed Development Plan
shall become the Development Plan.
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
15
- --------------------------------------------------------------------------------
4.2.2.2 Notwithstanding anything to the contrary in this
Agreement (including the provisions of Section 3.1 and Section 4.2.2.1 requiring
submission of disputes to arbitration), (a) if Advancis proposes to revise the
Development Plan in a manner that would (i) [***] and (b) if after following the
procedures in Section 4.2.2.1 the chief executive officers of the Parties fail
to agree as to the advisability of such proposed changes to the Development Plan
within [***] after referral of the matter to them, then Par shall have the right
for a period of [***] following the written notice by the chief executive
officer of either party to the other Party that the Parties have failed to agree
on the proposed changes to the Development Plan (the "SECTION 4.2.2.2 PERIOD"),
to terminate this Agreement upon 30 days' prior written notice to Advancis. If
the Section 4.2.2.2 Period expires without Par delivering a written notice of
termination to Advancis, then this Agreement shall remain in force.
4.2.2.3 In the event that Par rightfully terminates this
Agreement in accordance with the provisions of Section 4.2.2.2, then (i) no
Development Funding Gap amounts shall be due or payable; and (ii) if such
termination occurs after Par has paid to Advancis in cash at least $20,000,000
in Development Costs and Advancis successfully commercializes the Products then
Advancis shall reimburse Par for [***] (the "SECTION 4.2.2.3 Amount") following
the successful commercialization of the Products by making [***] to Par equal to
[***] on sales of the Products [***] until Advancis has refunded to Par the
Section 4.2.2.3 Amount.
4.2.3 Any and all additional development costs explicitly
included in the Development Plan revised in accordance with Section 4.2.2 of
this agreement shall constitute Development Costs, subject only to the rights of
the Parties under Section 4.2.2.3 and Section 12.3 if this Agreement is
terminated pursuant to Section 4.2.2.
4.3 CLINICAL AND REGULATORY APPROVAL.
4.3.1 CONDUCT BY ADVANCIS. Under Advancis's direction and
control, Advancis agrees [***] (a) to conduct required clinical trials of the
Products and obtain Regulatory Approval in accordance with the Development Plan
and (b) to include Par in such efforts in a consultative capacity; provided,
however, for purposes of clarity, Par shall not have the right to direct or
control Advancis' conduct of such clinical trials.
4.3.2 REGULATORY SUBMISSIONS. The Parties acknowledge that the
Products have not been reviewed or approved for sale or use for any purpose by
any governmental or regulatory body. Advancis shall prepare any required
application(s) for Regulatory Approval. Advancis shall own in their entirety (a)
all clinical data and reports related to Product Studies including clinical
trials for the Products and (b) all NDAs and other Regulatory Approvals for
Products. Advancis shall [***] to inform Par of all communications with the FDA
and to provide copies of FDA submissions to the Development and Manufacturing
Subcommittee prior to their submission to FDA. The Parties shall cooperate in
good faith with respect to, and Advancis shall [***] to enable representatives
of Par to attend all formal meetings with the FDA relating to regulatory
approval of the Products. The Parties shall cooperate in good faith with
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
16
- --------------------------------------------------------------------------------
respect to the conduct of any inspections by any regulatory authority of a
Party's site and facilities related to the Products. To the extent either Party
receives written or material oral communication from the FDA or any other
regulatory authority relating to any Regulatory Approval process with respect to
the Products, the Party receiving such communication shall notify the other
Party and provide a copy of any written communication as soon as reasonably
practicable.
4.4 DEVELOPMENT PROGRAM FUNDING. Par shall make the payments for
Development Costs in accordance with Section B.10 of Exhibit B. If in any
calendar year Advancis anticipates a Development Funding Gap or there is a
Development Funding Gap, within its sole discretion, Advancis shall have the
right (a) to continue to incur and self-fund the Development Costs for such
calendar year and/or (b) to procure third party funding of such shortfall and/or
(c) to modify or delay the Development Plan in order to adjust the amount or
timing of funds needed thereunder to match the payments being made by Par
pursuant to Exhibit B. Provided that Advancis shall [***] to notify Par
quarterly of the Development Costs incurred by Advancis in accordance with this
Agreement as they are incurred during Term; nothing herein shall restrict
Advancis's right to reasonably delay or withhold its invoicing of Development
Costs incurred under this Agreement pursuant to the foregoing items (a), (b) and
(c) of this Section 4.4. Any delay in the Development Plan pursuant to this
Section 4.4 [***] by Advancis. To the extent that there is a Development Funding
Gap, such Development Funding Gap shall be reimbursed to Advancis out of Par's
share of Operating Profits in accordance with Exhibit B.
4.5 DEVELOPMENT PROGRAM REPORTING.
4.5.1. Advancis shall provide Par at regularly scheduled meetings
of the Development and Manufacturing Subcommittee with summary updates regarding
the progress of the Development Program and Regulatory Approval process.
4.5.2. Advancis shall advise Par of any unforeseen material
problems or delays encountered since the date of its last report in connection
with the Development Program.
4.5.3. Advancis shall provide Par as soon as reasonably
practicable with such other material information as Par may reasonably request
in writing or through Advancis's Alliance Manager from time to time with respect
to the status of the Development Program.
ARTICLE V
COMMERCIALIZATION ACTIVITIES
5.1 SHARED RESPONSIBILITY AND CONTROL. The Parties agree and
acknowledge that both Parties shall share responsibility and control for
Commercialization of the Products in the Territory in accordance with the terms
of this Agreement and the Commercialization Plans. The Parties shall keep each
other apprised of and consult with each other regarding their respective
Commercialization activities for the Products on a regular basis through the
Sales and Marketing Subcommittee and, to the extent appropriate, the Executive
Committee.
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
17
- --------------------------------------------------------------------------------
5.2 COMMERCIALIZATION PLANS.
5.2.1 NEGOTIATION AND APPROVAL. For each calendar year, the Sales
and Marketing Subcommittee shall be responsible for preparing a detailed plan
and budget for the Premarketing Program and the Commercialization of Products in
the United States for submission to the Executive Committee (each, a "DRAFT
PLAN"). Each Draft Plan shall be reviewed by the Executive Committee, and the
Executive Committee shall have the right to amend or revise each Draft Plan
prior to approval thereof. A Draft Plan with any amendments or revisions as
approved by the Executive Committee shall be a "COMMERCIALIZATION PLAN." The
initial Commercialization Plan shall be consistent with the Preliminary
Commercialization Plan and shall address the matters specified in Exhibit C;
provided, that if (a) [***] or (b) [***], then the initial Commercialization
Plan shall include such departures from the Preliminary Commercialization Plan
and Exhibit C as are approved by the Executive Committee. Additionally, for
purposes of clarity, the parties understand and agree that [***] and shall be
addressed in the initial Commercialization Plan. The Finance Subcommittee shall
assist the Sales and Marketing Subcommittee and the Executive Committee in the
preparation of the budget portion of each Commercialization Plan.
5.2.2 Beginning with the year 2005, on or before April 1 of each
calendar year during the term, the Sales and Marketing Subcommittee shall
commence preparation of an annual Draft Plan for the next succeeding calendar
year. Each such proposed annual Draft Plan shall be submitted for approval by
the Executive Committee on or before June 1 of such calendar year. The Executive
Committee may adopt any proposed Draft Plan with or without modification. If the
Executive Committee fails to adopt an annual Commercialization Plan prior to
September 30 of a calendar year, then the Commercialization Plan then in effect
shall remain in effect for the following until the adoption of a new
Commercialization Plan. Notwithstanding the foregoing provisions, the first
annual Draft Plan shall be prepared as follows: as soon as practical after the
Effective Date, the Sales and Marketing Subcommittee shall commence preparation
of an annual Draft Plan for calendar year 2005 and shall submit such proposed
annual Draft Plan for approval by the Executive Committee on or before December
1, 2004. Upon receipt of such proposed Draft Plan, and subject to Baseball
Arbitration, the Executive Committee shall negotiate in good faith and take such
other steps as may be necessary to adopt an initial Commercialization Plan as
promptly as practicable.
5.2.3 CONDUCT OF COMMERCIALIZATION EFFORTS. Each of the Parties
shall [***] to conduct its Commercialization efforts in accordance with the
then-current Commercialization Plan. The Parties shall comply, and shall require
all of their third party agents and contractors, if any, to comply, with all
applicable laws in the conduct of their Commercialization activities hereunder.
The Parties agree to Commercialize the Products only under the Product
Trademarks, the names of the Parties and, if applicable, the Advancis Slogan.
The foregoing notwithstanding, the Product Label may include the names of
manufacturers or other parties to the extent required by Applicable Law.
5.2.4 CO-PROMOTION.
5.2.4.1 Both Parties shall have the right to Promote the
Products for sale in the Territory. All materials created or used for the
Promotion of the Products, in any media, including all written, graphic,
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
18
- --------------------------------------------------------------------------------
electronic, audio and video pieces and including journal advertisements, direct
mail, direct to consumer advertising, internet postings and web sites, broadcast
advertisements and giveaway items such as pens, cups, note pads and the like,
and all Product packaging and labeling, are referred to as the "PROMOTIONAL
MATERIALS."
5.2.4.2 Each Commercialization Plan shall allocate
responsibility between the Parties for the development, creation and
distribution of the Promotional Materials. The final forms of all Promotional
Materials shall require the mutual approval of both Parties prior to their
distribution or use. Advancis shall have responsibility for and sole control
over any filings required to be made with the FDA in connection with the
Promotional Materials and the Parties' Commercialization activities. In their
Promotion of the Products, the Parties shall only utilize the Promotional
Materials and shall not use promotional materials relating to any other product.
Promotional Materials shall be allocated to each Party according to each Party's
Detailing Requirements for the applicable period or as otherwise provided in the
applicable Commercialization Plan.
5.2.4.3 All Commercialization activities conducted by the
Parties shall be consistent with the Promotional Materials so approved and the
then-current Commercialization Plan.
5.2.4.4 Advancis shall own all copyrights in the Promotional
Materials. Par hereby assigns all right, title and interest in and to all
copyrights in the Promotional Materials to Advancis. Par shall execute whatever
reasonable additional documents Advancis deems necessary or appropriate to vest
in Advancis such rights in and to the copyrights in Promotional Materials it
creates or commissions. Par shall cause any third party engaged by Par to
create, in whole or in part, any Promotional Materials to execute whatever
assignments and other documents Advancis deems necessary or appropriate to vest
in Advancis such copyrights in and to the Promotional Materials. Par shall
inform any such third party of the requirements of this Section 5.2.4.4 prior to
engaging its services.
5.2.4.5 All Promotional Materials shall bear the corporate
names and logos/trademarks of each Party in substantially equal prominence and
frequency. All Promotional Materials also shall bear one or more of the Product
Trademarks and the Advancis Slogan, if applicable.
5.2.5 DISTRIBUTION; PRICING.
5.2.5.1 Advancis hereby appoints Par as Advancis's sole
distributor of the Products in the Territory. Accordingly, Par shall be solely
responsible for the sale and distribution of the Products in the Territory under
the Commercialization Plans, including (a) booking sales, (b) handling all
returns, (c) handling all aspects of order processing, invoicing and collection
of receivables, (d) collecting data regarding sales to hospitals and other end
users, (e) monitoring inventory levels, and (f) warehousing. Par shall provide
all such sales and distribution activities in accordance with the
Commercialization Plans and shall store and distribute the Products in full
compliance, and otherwise fully comply, with all applicable laws, including the
requirements of the PDMA.
19
- --------------------------------------------------------------------------------
5.2.5.2 Notwithstanding the foregoing provisions; (a) the
Parties shall be jointly responsible for all pricing decisions, including
decisions relating to customer allowances and credits, as well as any discounts
and rebates; and (b) if Par, its Affiliates or their Marketing Distributors sell
Products to a customer who also purchases other products or services from any
such entity, Par agrees not to, and to require its Affiliates and their
Marketing Distributors not to, discount, price or otherwise Promote Products in
a manner that disadvantages Products in order to benefit sales or prices of
other products or services offered for sale by Par, its Affiliates or their
Marketing Distributors to such customers.
5.2.6 PRODUCT SALES FORCE; DEPLOYMENT AND CONTROL. Each Party
hereby agrees that it will hire, train, and deploy Sales Representatives
comprising its Product Sales Force in such numbers as are agreed in the
then-current Commercialization Plan and at such times with respect to each
Product for the Targeted Prescribers to ensure compliance with all Detailing
Requirements of such Commercialization Plan. Each Party shall have exclusive
control over its own Product Sales Force; provided, however that each Party
shall train its Product Sales Force in accordance with the training guidelines
established by the Sales and Marketing Subcommittee. Each Party recognizes the
importance of establishing its Product Sales Force in advance of the launch of
the Products and agrees to [***] to deploy its Product Sales Force at least one
month prior to the first commercial launch of any Product. Nothing in this
Agreement shall be construed to mean that any Sales Representatives of one Party
are agents or employees of the other Party or under the direction or control of
the other Party. Each Party shall have sole control over the terms and
conditions of its Sales Representatives' hiring, employment and termination;
provided however, that each Party shall cause its Product Sales Force to provide
sales services in accordance with any guidelines or standards established by the
Sales and Marketing Subcommittee. Each Party shall be solely responsible for
compensating its own Sales Representatives, including paying salaries and
expenses, providing benefits, deducting taxes, and the like. Notwithstanding
anything else to the contrary, [***]. Subject to the preceding sentence, the
Commercialization Plan shall set forth the percentage of the Total Details to be
performed by each Party and to the extent that a Party is to perform more than
[***] of the Total Details, the Commercialization Plan shall set forth the
amount to be paid to such Party by the other Party to fairly compensate such
Party for performing such excess Details based on Product Sales Force Costs of
such Party.
5.2.7 DETAILING REPORTS. Each Party shall provide the other Party
with a report as soon as practicable but in no event later than forty-five (45)
days following the end of each month setting forth, in such detail and form as
the Parties shall agree, the number of Details made and the amount of Samples
distributed by such Party's respective Sales Representatives in the United
States during such month, provided, that the report for the final month in each
calendar year shall be cumulative and reflect the number of Details made and
Samples distributed by such Party's respective Sales Representatives in the
United States during such calendar year.
5.2.8 PREMARKETING AND PROMOTION COSTS. As set forth in Exhibit B
the parties shall equally share Premarketing Costs and Promotion Costs for all
Products.
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
20
- --------------------------------------------------------------------------------
5.2.9 SAMPLES. Following the first commercial launch of any
Product and in support of each Party's Detailing and Promotional activities
hereunder, Advancis shall provide Par with Samples in accordance with Section
8.2 and as required in the then-current Commercialization Plan. Samples shall be
allocated between the Product Sales Force of each Party in accordance with the
number of Details the respective field forces are required to undertake as set
forth in the then-current Commercialization Plan. Advancis and Par shall use
Samples strictly in accordance with the applicable Commercialization Plan and
shall store and distribute such Samples in full compliance, and otherwise fully
comply, with all applicable laws, including the requirements of the PDMA.
Advancis and Par each will maintain those records required by the PDMA and all
other laws with respect to the Samples allocated to each of them. Each of
Advancis and Par shall be responsible for the filing of any reports required by
the PDMA with respect to the Samples allocated to it. Each Party shall destroy
any Samples not distributed by its Sales Representatives at such Party's sole
expense.
5.2.10 HEALTHCARE PROFESSIONAL INQUIRIES. The Sales and Marketing
Subcommittee, working in conjunction with the other Subcommittees, shall develop
and provide the Parties with written information and materials appropriate for
distribution by the Parties' Sales Representatives to health care professionals
and consumers relating to each FDA-approved use of the Products; provided that
final forms of all such written information and materials shall be mutually
approved by the Parties. Par shall promptly forward to Advancis any medical
questions or inquiries Par receives from health care professionals or consumers
relating to the Products which questions or inquiries require a response other
than delivery of such pre-approved information or materials. The Sales and
Marketing Subcommittee shall develop and provide Advancis with such additional
written information and materials as Advancis may request to allow Advancis'
medical professionals to respond to medical questions or inquiries concerning
all other matters relating to the Products in accordance with Advancis's
policies and procedures for responding to unsolicited medical inquiry requests
on off-label use.
5.3 ADDITIONAL PARTIES TO COMMERCIALIZATION EFFORTS.
5.3.1 Either Party may contract with third party vendors and
contractors, such as contract sales organizations, in order to meet such Party's
obligations under the then-current Commercialization Plan; provided that (i)
such Party shall remain fully responsible for its compliance with all such
obligations, and (ii) the contracting Party shall have obtained the prior
written consent of the other Party (such consent not to be unreasonably withheld
or delayed) to the terms and conditions on which any such third party vendors or
contractors will provide their services. Subject to Section 5.2.6, if and to the
extent that either Party notifies the other Party that such Party is unable to
meet such Party's obligations under the then-current Commercialization Plan, the
other Party shall have the option to increase its Commercialization activities
so that the Parties, together, meet the aggregate targets specified in the
then-current Commercialization Plan.
5.3.2 The Parties anticipate that, in order to successfully
implement the Commercialization Plans, it may be necessary or advisable to
collaborate with an additional party that can provide material assistance to the
Parties with respect to some or all of the items in the then-current
Commercialization Plan at a level consistent with the efforts contemplated to be
provided by the Parties, including, by way of example, a third party agreement
to assume responsibility for the marketing and sale of a Product to a particular
21
- --------------------------------------------------------------------------------
prescriber base for a given Indication. Notwithstanding the foregoing, to the
extent the Parties do not enter into a further collaboration with any such third
party, the Parties shall undertake their Commercialization efforts in accordance
with the then-current Commercialization Plan, including all Detailing
Requirements and related matters.
5.4 TRADEMARKS.
5.4.1 It is the intent of the Parties that a new primary
trademark shall be developed for use on and in connection with the
Commercialization of Products in the Territory (the "PRINCIPAL TRADEMARK"). The
Principal Trademark and any other related trademarks, logos, trade names, and
similar source identifiers that are created or selected for use in connection
with the Commercialization of the Products are referred to collectively as the
"PRODUCT TRADEMARKS." In addition, Advancis will develop and, from time to time,
modify in its sole reasonable discretion, a slogan for use on and in connection
with its products, including the Products (the "ADVANCIS SLOGAN"). The Product
Trademarks shall not include any trademarks, logos, trade names or similar
source identifiers that (i) are owned or licensed by Advancis as of the
Effective Date, including the names and marks ADVANCIS and PULSYS, the Advancis
Slogan, any other marks created, acquired or licensed by Advancis at any time
for use in connection with products other than the Products, and any marks
consisting, in whole or in part, of such marks (the "ADVANCIS MARKS"); or (ii)
are owned or licensed by Par as of the Effective Date, including the name and
mark PAR, any marks consisting, in whole or in part, of such mark, and any other
marks created, acquired or licensed by Par at any time for use in connection
with products other than the Products (collectively, the "PAR MARKS").
5.4.2 The Product Trademarks each shall be selected by Advancis
subject to consent of Par, such consent not to be unreasonably withheld or
delayed. Advancis shall be the sole owner of all worldwide rights in the Product
Trademarks. Advancis shall use Commercially Reasonable Efforts to search and
clear rights to the Principal Trademark and to apply for, register and maintain
a U.S. federal trademark registration for the Principal Trademark; provided that
the costs (excluding legal fees) for such procurement and maintenance of such
trademark registration shall be shared by the Parties as provided in the
applicable Commercialization Plan and Financial Planning Schedule. Advancis
shall have the sole right and responsibility to decide whether to seek or
continue to seek or to maintain trademark rights and/or trademark
applications/registrations for any other Product Trademarks or in any other
country with respect to any Product Trademarks.
5.4.3 During the Term, in furtherance of the purposes and subject
to the terms and conditions of this Agreement, Advancis hereby grants Par the
non-exclusive, non-transferable, non-sublicensable, limited right and license to
use and display the Product Trademarks solely in connection with the
Commercialization of the Products in the Territory in accordance with the terms
of this Agreement and the Commercialization Plans and for no other purpose.
Advancis represents and Par acknowledges that Advancis is granting Par rights
only to the extent that Advancis has or acquires such rights.
5.4.4 Except as otherwise specified in this Agreement, the
Parties' Commercialization activities under the Product Trademarks shall be
subject to the oversight and control of the Sales and Marketing Subcommittee.
22
- --------------------------------------------------------------------------------
The Parties' respective representatives comprising the Sales and Marketing
Subcommittee shall establish and maintain a high and uniform standard of quality
for such Commercialization activities. The Parties shall use the Product
Trademarks solely in accordance with the reasonable Trademark Usage Guidelines
which shall be established by Advancis. Advancis may reasonably modify its
Trademark Usage Guidelines at any time and from time to time, and any such
modified guidelines shall become binding hereunder upon notice to Par. Par shall
cooperate fully and in good faith with Advancis to preserve and protect the
Product Trademarks.
5.4.5 Par acknowledges the great value of the goodwill that is or
will be associated with the Product Trademarks. Par agrees that it shall not
assert any claim of ownership to any Product Trademarks or otherwise interfere
with Advancis's sole and exclusive rights to the Product Trademarks. All
goodwill from use of the Product Trademarks by Par shall inure to the benefit of
Advancis, and Par shall not take any action in derogation of any of the rights
of Advancis in the Product Trademarks. To protect and preserve the goodwill
associated with the Product Trademarks, Par shall avoid deceptive, misleading or
unethical practices that are or might be detrimental to the Products, Advancis
or the public, and will refrain from publishing or employing any misleading or
deceptive advertising. Par shall not, during the Term or after termination of
this Agreement, register or attempt to register with any agency or in any
jurisdiction any Product Trademark or any mark confusingly similar therewith or
register any domain name comprised of a Product Trademark.
5.4.6 Advancis acknowledges the great value of the goodwill that
is or will be associated with the Par Marks. Advancis agrees that it shall not
assert any claim of ownership to any Par Marks or otherwise interfere with Par's
sole and exclusive rights to the Par Marks. All goodwill from use of the Par
Marks shall inure to the benefit of Par, Advancis shall not take any action in
derogation of any of the rights of Par in the Par Marks. To protect and preserve
the goodwill associated with the Par Marks, Advancis shall avoid deceptive,
misleading or unethical practices that are or might be detrimental to Par, or
the public, and will refrain from publishing or employing any misleading or
deceptive advertising. Advancis shall not, during the Term or after termination
of this Agreement, use, register or attempt to register with any agency or in
any jurisdiction any trademark or any mark confusingly similar with the Par
Marks or register any domain name comprised of a Par Mark.
5.4.7 Par acknowledges the great value of the goodwill that is or
will be associated with the Advancis Marks. Par agrees that it shall not assert
any claim of ownership to any Advancis Marks or otherwise interfere with
Advancis' sole and exclusive rights to the Advancis Marks. Par shall not take
any action in derogation of any of the rights of Advancis in the Advancis Marks.
To protect and preserve the goodwill associated with the Advancis Marks, Par
shall avoid deceptive, misleading or unethical practices that are or might be
detrimental to Advancis, or the public, and will refrain from publishing or
employing any misleading or deceptive advertising related to the Advancis Marks.
Par shall not, during the Term or after termination of this Agreement, use,
register or attempt to register with any agency or in any jurisdiction any
trademark or any mark confusingly similar with the Advancis Marks or register
any domain name comprised of an Advancis Mark.
23
- --------------------------------------------------------------------------------
5.4.8 Each Party shall notify the Alliance Managers promptly upon
learning of any actual, alleged or threatened infringement of any Product
Trademark applicable to a Product in the Territory, or of any unfair trade
practices, trade dress imitation, passing off of counterfeit goods, or like
offenses in the Territory. Upon learning of such offenses from a Party regarding
a Product Trademark, the Alliance Managers shall confer with the Parties
regarding the defense of the Product Trademark; provided, that the decision
whether and how to defend such Product Trademark shall rest with Advancis, and
Advancis shall have the sole right to respond to and defend any such
infringement or offense. To the extent Advancis elects to defend the Product
Trademark, it shall use Commercially Reasonable Efforts to protect, defend and
maintain the Product Trademark for use by the Parties in the Territory in
connection with the Product. The Parties shall cooperate in good faith with
respect to all Product Trademark enforcement actions hereunder, and each Party
shall notify the other Party promptly of all substantive developments with
respect to such Product Trademark enforcement actions, including all material
filings, court papers and other related documents. Advancis also shall have the
right to control settlement of any such infringement claim. The Parties shall
share equally the cost and expense of any action under this Section 5.4.8.
5.4.9 Each Party shall notify the Alliance Managers promptly upon
learning of any third-party claim of infringement or similar claim alleged or
brought against either Party relating to any Product Trademark. Upon learning of
such claim, the Alliance Managers shall confer with the Parties regarding the
appropriate response; provided, that the decision whether and how to defend
against such claim shall rest with Advancis, and Advancis shall have the sole
right to respond to and defend against any such claim. To the extent Advancis
elects to defend against such claim, it shall use Commercially Reasonable
Efforts to do so. The Parties shall cooperate in good faith with respect to all
such actions hereunder, and each Party shall notify the other Party promptly of
all substantive developments with respect to such actions, including all
material filings, court papers and other related documents. Advancis also shall
have the right to control settlement of any such claims. Advancis shall solely
bear the cost and expense of any such action or claim including any damages
payable to any Third Party.
ARTICLE VI
PAYMENTS
6.1 UPFRONT PAYMENTS. In consideration for the execution and delivery
of this Agreement by Advancis, Par shall pay Advancis a fully-earned,
non-refundable, non-creditable license fee in the amount of Five Million U.S.
Dollars (US$5,000,000) by wire transfer of immediately available funds upon
execution and delivery of this Agreement.
6.2 COLLABORATION PAYMENTS. Par shall pay Advancis collaboration
payments (collectively, "COLLABORATION PAYMENTS") based on the sale of Products
by Par (or its Affiliates or sublicensees, as applicable) in an amount equal to
[***] of Operating Profits, as set forth in the Financial Planning Schedule.
6.3 Par shall make payments to Advancis in the amounts and on the dates
set forth in Section B.10 of Exhibit B.
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
24
- --------------------------------------------------------------------------------
ARTICLE VII
INTELLECTUAL PROPERTY RIGHTS AND LICENSES
7.1 LICENSE GRANT.
7.1.1 Subject to the terms and conditions of this Agreement
including Advancis's rights pursuant to Sections 5.1 and 5.2, Advancis hereby
grants to Par an exclusive, nontransferable right and license, solely during the
Term (except as otherwise provided in Section 12.3) and in the Territory, under
all Advancis Patent Rights, Advancis Know-How and Program Developments, in each
case solely as embodied in the Products, to Promote, Detail, offer to sell, sell
and have sold in the Territory the Products purchased by Par from Advancis for
all approved human therapeutic uses.
7.1.2 Par shall not sell, distribute or transfer any Product to
any Person that, to Par's knowledge, is using any Product outside of the
Territory or is selling or transferring any Product to a Person who is using
such Product outside of the Territory.
7.1.3 Par agrees that during the Term it will use Advancis Patent
Rights, Advancis Know-How and Program Developments owned by Advancis only as
explicitly provided under this Agreement, in each case, in accordance with the
terms and conditions of this Agreement. Moreover, Par expressly acknowledges and
agrees that the only licenses granted under this Agreement are the licenses
expressly granted under this Agreement and that there shall be no implied
license or license by estoppel.
7.2 OWNERSHIP OF INTELLECTUAL PROPERTY. Par hereby acknowledges and
agrees that, as between Par and Advancis, (a) Advancis owns and shall continue
at all times to own all right, title and interest in and to the Advancis Patent
Rights and Advancis Know-How, including all intellectual property rights
appurtenant thereto, and (b) Advancis shall own all right, title and interest in
and to all Program Developments made by Advancis employees or Advancis's third
party contractors or made jointly with Par, including all intellectual property
rights appurtenant thereto. To the extent that Par employees are the sole
inventors of any Program Developments, Par shall be the sole owner of such
Program Developments, provided that Par gives written notice to Advancis of
Par's assertion of sole inventorship within a reasonable time frame following
the invention or discovery of such Program Development. Par hereby grants to
Advancis a limited non-exclusive license under all of its right, title and
interest, if any, in and to all such Program Developments to make, have made,
use, import, offer for sale and sell Products during the Term. To the extent
necessary to assign joint inventions, Par shall enter into and execute all
reasonable and appropriate assignments, transfers and other agreements, and
enter into all agreements with its employees, contractors and Affiliates, that
are necessary or appropriate to ensure the assignment of such Program
Developments to Advancis. The Parties shall cooperate fully with each other with
respect to patent filing, prosecution, and enforcement of all such Program
Developments, including cooperating in obtaining the execution of any necessary
documents by its employees and other persons under its control.
7.3 NON-USE OF TRADEMARKS. Except as set forth explicitly in this
Agreement, neither Party shall have the right to use the trademarks, trade names
or logos of the other Party, nor any adaptation thereof, nor the names of any
employees or consultants of the other Party, without the prior written consent
25
- --------------------------------------------------------------------------------
of the other Party in each instance, except that either Party may use the other
Party's name in its general list of collaborators and either party may use the
other Party's name to the extent required by applicable law, including pursuant
to the Securities Act of 1933, as amended, and the rules and regulations
thereunder.
ARTICLE VIII
MANUFACTURE AND SUPPLY
8.1 CLINICAL SUPPLIES. Advancis shall manufacture or cause to be
manufactured all Clinical Supplies of Product for the Development Program,
including the completion of pre-clinical work and human clinical trials with
respect to the Indications for the Products in the Territory. As soon as
practicable after the Effective Date Advancis shall negotiate and enter into one
or more manufacturing and supply agreements with one or more third party
contract manufacturers for the manufacture, supply and quality control of such
Clinical Supplies of the Products. Advancis's choice of such third party
contract manufacturer(s), and the terms and conditions of such manufacturing and
supply agreement(s), shall be subject to reasonable prior review by the
Development and Manufacturing Subcommittee (which includes the reasonable input
of Par). If a vote of the Development and Manufacturing Subcommittee disapproves
of the third party contract manufacturer(s) or the proposed manufacturing and
supply agreement for such Clinical Supplies, such dispute shall be referred to
the Executive Committee for review and discussion, provided that all
decision-making authority with respect thereto shall remain with Advancis, which
may enter into any such manufacturing and supply agreement over the objections
of the Development and Manufacturing Subcommittee and/or the Executive
Committee.
8.2 COMMERCIAL SUPPLIES. Advancis shall be responsible for establishing
a commercial manufacturing process and for manufacturing or causing to be
manufactured Commercial Supplies of the Products, at the scale and in the
amounts required to carry out the then-current Commercialization Plan. Advancis
shall negotiate and enter into one or more manufacturing and supply agreements
with one or more third party contract manufacturers for the manufacture, supply
and quality control of such Commercial Supplies of the Products as soon as
practicable after execution and delivery of this Agreement. Advancis's choice of
such third party contract manufacturer(s), and the terms and conditions of such
manufacturing and supply agreement(s) shall be subject to reasonable prior
review by the Development and Manufacturing Subcommittee (which includes the the
reasonable input of Par). If a vote of the Development and Manufacturing
Subcommittee disapproves of the third party contract manufacturer(s) or the
proposed manufacturing and supply agreement for such Commercial Supplies, such
dispute shall be referred to the Executive Committee for review and discussion;
provided that all decision-making authority with respect thereto shall remain
with Advancis, which may enter into any such manufacturing and supply agreement
over the objections of the Development and Manufacturing Subcommittee and/or the
Executive Committee.
8.3 SUPPLY AND DISTRIBUTION TERMS. The detailed terms of Advancis's
supply to Par of the Commercial Supplies shall be governed by a supply and
distribution agreement between the Parties (the "SUPPLY AGREEMENT"), which the
Parties agree to negotiate in good faith and use their Commercially Reasonable
Efforts to enter into as soon as practicable after the Effective Date on terms
26
- --------------------------------------------------------------------------------
substantially the same as those received from the third-party Product
manufacturer, except that the parties understand and agree that any allocations
of product liability as between the parties has not been agreed upon. The Supply
Agreement shall include a provision that the price for Product to be paid by Par
to Advancis shall be equal to the aggregate of (i) price paid for Product by
Advancis to the Third Party manufacturer, and (ii) other amounts which Advancis
is obligated to pay in relationship to the Product (including, e.g. shipping of
the Product) under a supply agreement for Product with a Third Party
manufacturer. In the event Advancis is unable to supply adequate Commercial
Supplies, Par shall have the right, subject and pursuant to the Supply
Agreement, to obtain such Commercial Supplies in any reasonable fashion as more
fully described in the Supply Agreement. Notwithstanding anything to the
contrary herein, if the Parties fail to agree on the terms of the Supply
Agreement within 180 days after the date hereof, either party may by written
notice cause the disputed provisions to be subject to resolution by arbitration
in accordance with Section 17.2.2.
ARTICLE IX
REPORTS AND RECORDS
9.1 Each of the Parties shall keep and maintain, and shall require its
Affiliates to keep and maintain, complete and accurate books in respect of its
respective obligations and activities under this Agreement, including such
activities for which payment may be required, in accordance with applicable
accounting principles consistently applied (including generally accepted
accounting principles) and in accordance with applicable law. Each Party and its
Affiliates shall maintain records in sufficient detail and in good scientific
manner appropriate for patent and FDA purposes and so as to properly reflect all
work done and results achieved in the performance of the Development Program,
the Premarketing Program, and Commercialization of the Products. Such records
may include, as applicable, books, records, reports, formulae, research notes,
charts, graphs, comments, computations, analyses, recordings, photographs,
computer programs and documentation thereof, samples of materials and graphic or
written data generated in connection with the Development Program and the
Premarketing Program, and Commercialization of the Products, including any data
required to be maintained pursuant to applicable governmental regulations. The
Parties and their Affiliates shall retain such records for five years after the
period to which such records relate, or for such longer or shorter period as the
Parties shall mutually determine.
ARTICLE X
CONFIDENTIAL AND TECHNICAL INFORMATION
10.1 TREATMENT OF CONFIDENTIAL INFORMATION. Each Party agrees to retain
in strict confidence and not to disclose, divulge or otherwise communicate to
any other person or entity any Confidential Information of the other Party,
whether received prior to or after the date hereof, and further agrees not to
use any such Confidential Information for any purpose, except pursuant to, and
in order to carry out, the terms and objectives of this Agreement, except that
each Party may disclose Confidential Information of the other Party to the
officers, directors, employees, agents, accountants, attorneys, consultants,
subcontractors or other representatives of the receiving Party or its Affiliates
(the "REPRESENTATIVES"), who, in each case, (a) need to know such Confidential
27
- --------------------------------------------------------------------------------
Information for purposes of the implementation and performance by the receiving
Party of this Agreement and (b) will use the Confidential Information only for
such limited purposes. Each Party hereby agrees to use at least the same
standard of care in complying with its confidentiality obligations hereunder as
it uses to protect its own Confidential Information of comparable sensitivity
and to exercise reasonable precautions to prevent and restrain the unauthorized
disclosure of such Confidential Information by any of its Representatives. Each
Party warrants that each of its Representatives to whom any Confidential
Information is revealed shall previously have been informed of the confidential
nature of the Confidential Information and shall have agreed to maintain its
confidentiality under terms no less restrictive than those set forth in this
Article X. Without limiting the generality of any of the foregoing, the parties
agree not to make any disclosure of Confidential Information that would be
reasonably likely to impair the Parties' ability to obtain U.S. or foreign
patents on any patentable invention or discovery described or otherwise embodied
in such Confidential Information. The Confidential Information of each Party
includes information from Third Parties disclosed by one Party to this Agreement
to the other Party to this Agreement.
10.2 RELEASE FROM RESTRICTIONS.
10.2.1 The provisions of Section 10.1 shall not apply to any
Confidential Information disclosed hereunder to the extent that such
Confidential Information is required to be disclosed by the receiving Party to
defend or prosecute litigation or to comply with applicable laws or regulations,
including filing an Information Disclosure Statement with the U.S. Patent and
Trademark Office or any other patent office, or pursuant to an order of a court
or regulatory agency, provided that the receiving Party shall provide prior
written notice of such disclosure to the other Party and shall take actions as
are reasonable and lawful to avoid and/or minimize the degree of such
disclosure. To the extent, if any, that a Party concludes in good faith that it
is required by applicable laws or regulations to file or register this Agreement
or a notification thereof with any governmental authority, including the U.S.
Securities and Exchange Commission, such Party may do so, and the other Party
shall cooperate in such filing or notification and shall execute all documents
reasonably required in connection therewith. In such situation, the filing Party
shall request confidential treatment of sensitive provisions of the Agreement,
to the extent permitted by law. The Parties shall promptly inform each other as
to the activities or inquiries of any such governmental authority relating to
this Agreement, and shall cooperate to respond to any request for further
information therefrom.
10.2.2 A Party may disclose this Agreement to a Third Party in
connection with or in conjunction with a proposed merger, consolidation, sale of
assets that include those related to this Agreement, an assignment of this
Agreement or loan financing, raising of capital, or sale of securities, provided
that the disclosing Party obtains an agreement for confidential treatment
thereof, except in the case where after reasonable efforts such Party is unable
to obtain such confidential treatment.
10.3 NO IMPLIED RIGHTS. Except as otherwise set forth in this
Agreement, nothing herein shall be construed as giving either Party any right,
title, interest in or ownership of the Confidential Information of the other
Party. For the purposes of this Agreement, specific information disclosed as
part of Confidential Information shall not be deemed to be in the public domain
or in the prior possession of the receiving Party merely because it is embraced
28
- --------------------------------------------------------------------------------
by more general information in the public domain or by more general information
in the prior possession of the receiving Party.
10.4 SURVIVAL OF CONFIDENTIALITY OBLIGATIONS. The confidentiality
obligations of the Parties contained in this Article X shall remain binding on
both Parties during the Term and for a period of five (5) years after the
termination of this Agreement, regardless of the cause of such termination. The
Parties acknowledge that any breach of this Article X will constitute
irreparable harm, and that the non-breaching Party shall be entitled to specific
performance or injunctive relief to enforce this Article X in addition to
whatever remedies such Party may otherwise be entitled to at law or in equity.
10.5 SUPERSEDING PRIOR CONFIDENTIALITY AGREEMENT. The provisions of
this Article X shall supersede the Confidentiality Agreement between the Parties
dated July 8, 2003 with respect to the subject matter hereof, and shall
establish the sole obligations of confidentiality and nonuse of Confidential
Information received by a Party prior to or after the Effective Date.
10.6 TAX TREATMENT. If a Party, or any Affiliate or Representative of a
Party, receives a statement made by or on behalf of the other Party, or any
Affiliate or Representative of the other Party, as to the tax consequences to
the other Party or its Affiliate of any of the arrangements, agreements, or
transactions provided for in this Agreement, then the receiving Party may
disclose as it wishes the tax treatment and tax structure of such arrangement,
agreement, or transaction, including any tax opinions or tax analyses related
thereto.
ARTICLE XI
PATENT PROSECUTION AND INFRINGEMENT
11.1 PATENT PROSECUTION AND MAINTENANCE.
11.1.1 Par shall inform Advancis promptly in reasonable detail of
any Program Developments by Par or any of its Affiliates or agents.
11.1.2 As between Advancis and Par, Advancis shall have the sole
right and responsibility to decide whether to seek or continue to seek or to
maintain patent protection in any country with respect to any Advancis Patent
Rights, Advancis Know-How and Program Developments owned by or licensed to
Advancis, and whether to file for, procure, maintain and enforce Patent Rights
in the Territory with respect to any Advancis Patent Rights and Program
Developments owned by or licensed to Advancis.
11.2 INFRINGEMENT.
11.2.1 Par and Advancis shall inform each other promptly in
writing of any alleged or suspected infringement by a Third Party of any of
Advancis Patent Rights, Advancis Know-How or Program Developments, and of any
available evidence thereof.
11.2.2 Subject to Sections 11.2.3 and 11.2.4, Advancis may, at
its sole option and expense, prosecute the infringement of any Advancis Patent
Rights, Advancis Know-How or Program Developments.
29
- --------------------------------------------------------------------------------
11.2.3 In the event that a Third Party infringes Advancis Patent
Rights, Advancis Know-How or Program Developments owned by Advancis by
manufacture, sale or use of a Product in the Territory (a "PRODUCT
INFRINGEMENT"), then the Parties shall discuss whether or not to institute an
infringement action with respect to such Product Infringement. If the Parties
agree to institute such a suit, then Advancis shall institute and control such
suit including the settlement or compromise thereof. Par shall, at the request
of Advancis, provide reasonable cooperation and, to the extent possible, have
its employees testify when requested and make available relevant records,
papers, information, Samples, specimens and the like. Advancis may join Par as a
party, and Par shall execute all papers and perform such acts as may be
reasonably required. The cost and expense of such suit shall be shared by the
Parties equally. Any royalties, payments, damages, expense, fees or other awards
(collectively, "DAMAGES"), received by Advancis and/or Par as a result of such
suit, whether through judgment or settlement, shall first be used to reimburse
each Party for its expenses associated with such infringement suit and then any
remainder shall be shared by the Parties equally, with such share of the Damages
to be paid to the other party, as applicable, as soon as practicable upon
receipt of the Damages.
11.2.4 In the event that only Advancis does not agree to
institute a suit against a Product Infringement pursuant to Section 11.2.3
within [***] of being notified of such alleged or suspected infringement, Par
may, at its option and expense prosecute such infringement of any Advancis
Patent Rights, Advancis Know-How or Program Developments owned by Advancis,
provided that Par can demonstrate through any industry recognized survey that
such sales of Product by the alleged or suspected infringer in the Territory
exceeds [***] of the sales in the Territory of the Product by Par during the
most recently completed [***] and [***]. However, Par shall not prosecute such
infringement if Advancis [***]. Such negotiation shall be conducted between the
Advancis and Par designees of the Executive Committee, and if agreement cannot
be reached, such [***] will be determined in accordance with the dispute
resolution process set forth in Section 17.2.2 herein. In any such infringement
suit Par may institute to enforce Advancis Patent Rights, Advancis Know-How or
Program Developments owned by Advancis, Advancis shall, at the request and
expense of Par, provide reasonable cooperation and, to the extent possible, have
its employees testify when requested and make available relevant records,
papers, information, Samples, specimens and the like. Par may join Advancis as a
party, and Advancis shall execute all papers and perform such acts as may be
reasonably required, at the expense of Par. Par shall bear all the cost and
expense of such suit and Par shall retain all payment, costs and damages
received as a result thereof, whether by judgment, settlement compromise or
otherwise Par shall not have the right to settle or compromise such action or
take any steps that adversely affect the scope, validity, enforceability or
ownership of Advancis Patent Rights or Advancis Know-How without the written
consent of Advancis.
11.2.5 In the event that only Par does not agree to institute
suit against a Product Infringement pursuant to Section 11.2.3 within [***] of
being notified of such alleged or suspected infringement, then Advancis shall
have the right to institute such an infringement suit at its cost and expense
and to retain all payment, costs and damages received as a result thereof,
whether by judgment, settlement compromise or otherwise.
11.2.6 In the event that a declaratory judgment action alleging
invalidity or non-infringement of any Advancis Patent Rights, Advancis Know-How
or Program Developments shall be brought against Advancis and/or Par, Advancis,
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
30
- --------------------------------------------------------------------------------
at its option, shall have the right, within [***] after commencement of such
action, to take over the sole defense of the action at its own expense. In the
event that Advancis does not so elect to take over the sole defense of the
action at its own expense, Par shall be free to proceed and solely control such
defense. To the extent that any Damages become payable to any Third Party as a
result of such action, whether through judgment or settlement, the Parties shall
bear such Damages equally, and shall contribute such share as promptly as
practicable. Any Damages received by Advancis and/or Par as a result of such
action, whether through judgment or settlement, shall first be used to reimburse
each Party for its expenses associated with such infringement suit not otherwise
reimbursed and then any remainder shall be shared by the Parties equally, with
such share of the Damages to be paid to the other party, as applicable, as soon
as practicable upon receipt of the Damages.
11.2.7 In the event that a third party institutes any suit
against Par and/or Advancis for patent infringement involving the Products, the
Party sued shall promptly notify the other Party in writing. Advancis shall
assume the defense of such suit, provided, however, that if Par is also a
defendant in such action and Par shall have reasonably concluded that there may
be legal defenses available to it that are different from or additional to those
available to Advancis, Par shall have the right to select separate counsel to
participate in such legal defenses on Par's behalf. The Parties shall share the
cost and expense of such defense equally. Each Party shall, at the other's
request, provide to it reasonable assistance and cooperation with respect to any
such suit. To the extent that any Damages become payable to any third party as a
result of such action, whether through judgment or settlement, the Parties shall
bear such Damages equally, and shall contribute such share as promptly as
practicable. Any Damages received by Advancis and/or Par as a result of such
action, whether through judgment or settlement, shall first be used to reimburse
each Party for its expenses associated with such infringement suit not otherwise
reimbursed and then any remainder shall be shared by the Parties equally, with
such share of the Damages to be paid to the other party, as applicable, as soon
as practicable upon receipt of the Damages.
11.2.8 If either Party becomes aware of a patent or patent
application that, when issued, might provide a basis for a Third Party argument
that its valid rights are being infringed by the manufacture, use or sale of the
Products hereunder, then such Party shall promptly inform the other Party of
such patent or patent application, and the Parties shall cooperate with each
other so that each Party can determine whether valid rights of a third party are
likely to be infringed by the manufacture, use or sale of the Products
hereunder.
11.2.9 If either Party believes that a license from a third party
is necessary to avoid infringement of patents of the third party, the Executive
Committee shall: 1) determine whether or not to seek such a license, 2) appoint
a negotiator to negotiate the terms of such a license, 3) determine whether or
not to enter into such a license as negotiated by the negotiator, and 4)
determine how the expenses of such a license shall be borne by the Parties. If
the Executive Committee cannot agree with regard to any responsibility set forth
in the preceding sentence, such issue shall be determined by arbitration in
accordance with Section 17.2.2.
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
31
- --------------------------------------------------------------------------------
ARTICLE XII
TERMINATION
12.1 TERM. The term of this Agreement shall commence upon the Effective
Date and shall end on the later of (a) the date upon which there is no Valid
Claim infringed by a Product in the Territory or (ii) the date which is [***]
from the date of first commercial sale of any Product, unless earlier terminated
in accordance with Section 12.2, provided, however, that either Party may elect
to extend the term for an additional period of [***] by giving written notice of
such extension to the other Party no later than [***] prior to such [***],
unless the Party receiving such notice of extension objects to such extension by
written notice to the Party seeking such extension within [***] after receiving
such notice of extension (such [***], to the extent so extended (if any) and
subject in all cases to earlier termination (if any), being referred to herein
as the "TERM").
12.2 TERMINATION EVENTS. In the event of (a) a material breach under
this Agreement by a Party, whether or not such material breach is specifically
described as such in this Agreement; (b) a Party becoming insolvent, or the
commencement against a Party, of any case or proceeding under any bankruptcy,
reorganization, insolvency or moratorium law, or any other law or laws for the
relief of debtors, or the appointment of any receiver, trustee or assignee to
take possession of the properties of such Party, unless such appointment is set
aside or withdraws or ceases to be in effect, within [***] after its
commencement or appointment; (c) the liquidation or dissolution of a Party; or
(d) the cessation of all or substantially all of a Party's business operations
(in each case, such Party being referred to as the "DEFAULTING PARTY"), then the
other Party (the "NON-DEFAULTING PARTY") shall have the right to terminate this
Agreement (including all licenses granted hereunder) upon [***] written notice
to the Defaulting Party, with such termination to become effective automatically
upon expiration of said [***], unless within said [***] the Defaulting Party
shall have cured such breach, if such breach is reasonably susceptible to cure
in such [***]; provided that, if such breach is not reasonably susceptible to
cure in such [***], then the Non-Defaulting Party shall not have the right to
terminate hereunder in the event that the Defaulting Party shall have commenced
to cure such breach and shall diligently be pursuing such cure; further
provided, that the notice and cure period for breaches arising out of the
failure to pay any obligations hereunder shall be limited to [***].
12.3 EFFECT OF TERMINATION OF AGREEMENT. Upon the expiration or
termination of the Term in accordance with Section 4.2.2, Section 4.2.4, Section
12.1 or Section 12.2 for any reason: (a) (except to the extent required pursuant
to clause (b) of this Section 12.3) all rights and licenses granted to Par
pursuant to this Agreement shall automatically and immediately terminate and Par
immediately shall discontinue Commercialization of Product and all use of the
Product Trademarks (and any word or design confusingly similar thereto) the
Advancis Know-How, Advancis Patent Rights and Program Developments owned by
Advancis; all worldwide rights in the Product Trademarks and the goodwill
related thereto shall remain the sole and exclusive property of Advancis; (b)
solely for a termination pursuant to Section 12.2 with respect to which Par is
the Non-Defaulting Party, and solely to the extent permitted by applicable law,
Par shall have the right to sell any Products on hand at the date of
termination, provided that all Collaboration Payments shall be paid and reports
made to Advancis with respect to such Products in accordance with this
Agreement; (c) except as provided in connection with the foregoing provision
12.3(b), Par promptly shall deliver to Advancis all Promotional Materials
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR
WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH
OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
32
- --------------------------------------------------------------------------------
and any other materials bearing the Product Trademarks and instruments used for
the purposes of affixing or displaying the Product Trademarks (to the extent
that such Promotional Materials or other Materials were paid for by Par and were
for use by Par, to the extent that they are thereafter used by Advancis,
Advancis shall reimburse Par for the cost of such Promotional Materials or
Materials); (d) Subject to Section 4.2.2.3 Par shall pay within thirty (30) days
after such termination: (i) all accrued and unpaid amounts due to Advancis in
accordance with the terms of this Agreement, including any unpaid Development
Costs due under Section B.10 of Exhibit B and any unpaid Collaboration Payments
with respect to all Products sold; and (ii) any other amounts that will become
due to Advancis through or after the effective date of such termination; and (d)
each Party shall return to the other Party, or destroy, at the other Party's
request, all Confidential Information of the other Party. Except with respect to
any termination of this Agreement pursuant to Section 4.2.1 (for which Section
4.2.2.2 shall apply) or pursuant to Section 12.2 with respect to which Par is
the Non-Defaulting Party, on the date of termination, if there is a Development
Funding Gap, within [***] thereafter Par shall pay to Advancis the lesser of the
Development Funding Gap or an amount such that the aggregate of such amount and
the amounts previously paid under Section B.10 of Exhibit B equals twenty eight
million dollars ($28,000,000.00).
12.4 SURVIVAL. In addition to all rights that have accrued as of the
date of termination, the following provisions shall survive the termination of
this Agreement for whatever reason: Articles X, XIII, XV, XVII, and XVIII, and
Sections 4.2.2.3, 5.4.2, 5.4.5, 12.3, 12.4, and 12.5. In addition, any other
provision required to interpret and enforce the Parties' rights and obligations
under this Agreement shall also survive, but only to the extent required for the
observation and performance of the aforementioned surviving rights or portions
of this Agreement.
12.5 REMEDIES. Upon the occurrence of any event set forth in Section
12.2 or any other breach of any provision of this Agreement, in addition to the
termination rights or other rights set forth herein, each Party shall have all
other rights and remedies at law or in equity to enforce this Agreement.
ARTICLE XIII
INDEMNIFICATION
13.1 INDEMNIFICATION BY PAR. Par shall at all times during the term of
this Agreement and thereafter, indemnify, defend and hold Advancis, its
officers, directors, employees and agents and Affiliates, and the successors and
assigns of the foregoing ("ADVANCIS INDEMNIFIED PARTIES"), harmless from and
against all expenses, damages, costs and liabilities of any kind whatsoever,
including legal expenses and reasonable attorneys' fees as a result of a Third
Party claim, suit, or cause of action (collectively, "LOSSES"), arising out of
the material breach by Par of any representation, warranty or obligation of Par
hereunder, or by a failure of Par to comply with all applicable laws, or the
negligence or willful misconduct of Par, except for Losses that arise solely out
of the gross negligence or intentional misconduct or illegal act of Advancis
Indemnified Partiesor to the extent Advancis is obligated to indemnify Par under
Section 13.2.
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
33
- --------------------------------------------------------------------------------
13.2 INDEMNIFICATION BY ADVANCIS. Advancis shall at all times during
the term of this Agreement and thereafter, indemnify, defend and hold Par, its
officers, directors, employees and agents and Affiliates, and the successors and
assigns of the foregoing ("PAR INDEMNIFIED PARTIES"), harmless against all
Losses arising out of the material breach by Advancis of any representation,
warranty or obligation of Advancis hereunder, or by a failure of Advancis to
comply with all applicable laws, or the negligence or willful misconduct of
Advancis, except for Losses that arise solely out of the gross negligence or
intentional misconduct or illegal act of Par Indemnified Parties or to the
extent Par is obligated to indemnify Advancis under Section 13.1.
13.3 CONDITIONS TO INDEMNIFICATION FOR THIRD PARTY CLAIMS. A Party that
intends to claim indemnification under this Article XIII (the "INDEMNITEE")
shall promptly notify the Indemnifying Party (the "INDEMNITOR") of any Losses in
respect of which the Indemnitee intends to claim such indemnification, and the
Indemnitor shall assume the defense thereof with counsel mutually satisfactory
to the Parties, whether or not the underlying third party claim is rightfully
brought. In addition to counsel provided by the Indemnitor, an Indemnitee shall
have the right to retain its own counsel at its own cost in such proceedings.
The indemnity agreement in this Article shall not apply to amounts paid in
settlement of any loss, claim, damage, liability or action if such settlement is
effected without the consent of the Indemnitor, which consent shall not be
withheld or delayed unreasonably. The failure to deliver notice to the
Indemnitor within a reasonable time after the Indemnitee has knowledge of any
Losses, if prejudicial to the Indemnitor's ability to defend such action, shall
relieve the Indemnitor of any liability to the Indemnitee under this Article. At
the Indemnitor's request, the Indemnitee, and its employees and agents, shall
cooperate fully with the Indemnitor and its legal representatives in the
investigation and defense of any third-party action, claim or liability covered
by this indemnification and provide full information with respect thereto. The
Indemnitor shall not settle or compromise any such third party claim without the
written consent of the Indemnitee, which consent shall not be unreasonably
withheld, but such consent shall not be required if the settlement or compromise
involves only the payment of monies and the Indemnitee obtains a complete
release thereunder.
13.4 INDEMNIFICATION FOR INFRINGEMENT CLAIMS. The provisions of this
Article XIII shall supplement the terms of Section 11.2 with respect to
third-party patent infringement claims. In the event of a conflict between this
Article XIII and Section 11.2, the terms of Section 11.2 shall control.
ARTICLE XIV
REPRESENTATIONS AND WARRANTIES
14.1 LEGAL AUTHORITY. Each Party represents and warrants to the other
as follows: (a) Such Party it has the legal power, authority and right to enter
into this Agreement and to perform its respective obligations set forth herein;
and (b) this Agreement has been duly executed and delivered by such Party and
constitutes the valid and binding obligation of such Party, enforceable against
such Party in accordance with its terms, except as enforceability may be limited
by bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and
other laws relating to or affecting creditors' rights generally and by general
equitable principles.
34
- --------------------------------------------------------------------------------
14.2 NO CONFLICTS. Each Party represents or warrants that as of the
date of this Agreement it is not a party to any agreement or arrangement with
any third party or under any obligation or restriction, including pursuant to
its corporate charter, bylaws or comparable governing documents, which in any
way limits or conflicts with its entering into this Agreement or its ability to
fulfill any of its obligations under this Agreement. Additionally, Advancis
represents and warrants that the Products that are the subject of the
development efforts under the Development plan do not and shall not meet the
test described in Exhibit A.
ARTICLE XV
LIMITATION OF LIABILITY
15.1 LIMITATION OF DAMAGES. EXCEPT TO THE EXTENT BREACHES OF ARTICLE
VII (INTELLECTUAL PROPERTY RIGHTS AND LICENSES) OR ARTICLE X (CONFIDENTIAL
INFORMATION) REQUIRE PAYMENT OF SUCH DAMAGES TO A THIRD PARTY OR THAT AMOUNTS
ARE PAYABLE TO A THIRD PARTY UNDER ARTICLE XIII, NEITHER PARTY NOR ANY OF ITS
REPRESENTATIVES OR AFFILIATES SHALL BE LIABLE TO THE OTHER PARTY FOR INCIDENTAL
OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO
PROPERTY AND LOST PROFITS (EXCEPT TO THE EXTENT OF ACCRUED COLLABORATION
PAYMENTS), REGARDLESS OF WHETHER SUCH PARTY SHALL BE ADVISED, SHALL HAVE OTHER
REASON TO KNOW OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING.
15.2 NO IMPLIED WARRANTIES BY ADVANCIS. EXCEPT AS OTHERWISE EXPRESSLY
SET FORTH IN THIS AGREEMENT, ADVANCIS AND ITS REPRESENTATIVES AND AFFILIATES
MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED, INCLUDING (A) REPRESENTATIONS AND WARRANTIES REGARDING THE PRODUCTS,
THE ADVANCIS PATENTS, THE ADVANCIS KNOW-HOW OR ANY TECHNOLOGY RELATED THERETO,
THE ADVANCIS MARKS OR THE PRODUCT TRADEMARKS AND (B) ALL WARRANTIES OF
MERCHANTABILITY, NON-INFRINGEMENT, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF
PATENT RIGHTS CLAIMS, ISSUED OR PENDING, ALL OF WHICH ARE HEREBY DISCLAIMED.
15.3 NO IMPLIED WARRANTIES BY PAR. EXCEPT AS OTHERWISE EXPRESSLY SET
FORTH IN THIS AGREEMENT, PAR AND ITS REPRESENTATIVES AND AFFILIATES MAKE NO
REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED,
INCLUDING WARRANTIES REGARDING THE PRODUCTS, ANY INTELLECTUAL PROPERTY OR
TECHNOLOGY RELATED THERETO, OR WARRANTIES OF MERCHANTABILITY,
NON-INFRINGEMENTAND FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE HEREBY
DISCLAIMED.
35
- --------------------------------------------------------------------------------
ARTICLE XVI
ADVERSE EVENTS; INSURANCE
16.1 ADVERSE EVENTS AND RECALL. Each Party shall give the other
immediate notice, which shall be promptly confirmed in writing, of any
occurrence that involves (i) any material complaint about the safety or
effectiveness of any Product, including a claim of death or injury; and (ii) any
other matter arising out of this Agreement that must be reported to a
governmental authority. If either Party believes it may be necessary or
desirable to conduct a recall, field correction, market withdrawal, stock
recovery or other similar action with respect to any Product sold under this
Agreement (a "RECALL"), the Parties shall promptly consult with each other as to
how best to proceed, it being understood and agreed that the final decision as
to any Recall of any Product shall be made by the Parties jointly; provided,
however, that neither Party shall be prohibited hereunder from taking any action
that it is required to take under applicable law. The cost of any Recall shall
be shared equally by the Parties, except that any Recall required because of a
negligent or illegal act or omission in the handling, storage or distribution of
Product by Par shall be at Par's sole expense.
16.2 INSURANCE BY PAR. Prior to the first sale or use in humans,
whichever is earlier, of a Product (excluding any such sale or use by Advancis),
Par shall obtain and carry in full force and effect commercial, general
liability insurance, including product liability and errors and omissions
insurance, which shall protect Par and Advancis with respect to events covered
by Section 13.1 above. Such insurance (a) shall be written by a reputable
insurance company authorized to do business in the State of Maryland; (b) shall
list Advancis as an additional named insured thereunder; (c) shall be endorsed
to include product liability coverage; and (d) shall require not less than
thirty (30) days written notice to be given to Advancis prior to any
cancellation or materials change thereof. The limits of such insurance shall not
be less than the amounts reasonably agreed to by the parties, which shall be
consistent with industry norms and customs. Par shall promptly provide Advancis
with Certificates of Insurance evidencing the same and shall not during the Term
materially decrease such coverage or cancel such insurance without written
approval from Advancis.
16.3 INSURANCE BY ADVANCIS. Prior to the first sale or use in humans,
whichever is earlier, of a Product (excluding any such sale or use by Par),
Advancis shall obtain and carry in full force and effect commercial, general
liability insurance, including product liability and errors and omissions
insurance, which shall protect Par and Advancis with respect to events covered
by Sections 13.2 above. Such insurance (a) shall be written by a reputable
insurance company authorized to do business in the State of New Jersey; (b)
shall list Par as an additional named insured thereunder, (c) shall be endorsed
to include product liability coverage; and (d) shall require not less than
thirty (30) days written notice to be given to Par prior to any cancellation or
material change thereof. The limits of such insurance shall not be less than the
amounts reasonably agreed to by the parties, which shall be consistent with
industry norms and customs. Advancis shall promptly provide Par with
Certificates of Insurance evidencing the same and shall not during the Term
materially decrease such coverage or cancel such insurance without written
approval from Par.
36
- --------------------------------------------------------------------------------
ARTICLE XVII
DISPUTE RESOLUTION
17.1 GOOD FAITH NEGOTIATIONS. In the event of any dispute or
disagreement between the Parties as to the interpretation of any provision of
this Agreement or the performance of obligations hereunder, the matter, upon
written request of either Party, shall first be referred to the chief executive
officers of the Parties for decision. Such chief executive officers shall
promptly meet in a good faith effort to resolve the dispute.
17.2 ARBITRATION.
17.2.1 GENERALLY. Except as provided in Section 17.2.2, if any
dispute described in Section 17.1 other than a dispute that arises under the
patent laws of a country cannot be resolved by the chief executive officers of
the Parties within [***] after its submission, then such dispute shall be
settled by binding arbitration held in Wilmington, Delaware in accordance with
the Commercial Arbitration Rules of the American Arbitration Association except
that (a) there shall be three U.S.-licensed attorneys acting as arbitrators, (b)
the arbitration proceedings shall be kept confidential and shall not be
disclosed to the public and (c) payment of the expenses of the arbitration,
including legal fees for both Parties and the fee of the arbitrators, shall be
assessed by the arbitrators based on the extent to which each party prevails.
Each Party shall select one arbitrator. The two arbitrators selected by the
Parties shall select the third arbitrator. At least one of the arbitrators shall
be a licensed attorney who has represented pharmaceutical companies for at least
ten years and is knowledgeable concerning the type of subject matter at issue in
the dispute. The award of the arbitrators shall be in writing and shall be
binding on the Parties, and judgment upon the award rendered by the arbitrators
may be entered in any federal court having jurisdiction. Any decision or award
made by the arbitrators shall be in accordance with the terms and conditions of
this Agreement and shall not be inconsistent with the rights and obligations of
the Parties as set forth in this Agreement. Nothing in this Agreement bars the
right of either Party to obtain preliminary or permanent injunctive relief
against threatened conduct that will cause it loss or damage, in accordance with
the rules for obtaining injunctive relief in any jurisdiction, including the
applicable rules for obtaining restraining orders and preliminary injunctions.
17.2.2 BASEBALL ARBITRATION. Notwithstanding anything to the
contrary in Section 17.2.1, if the Parties or a committee or subcommittee
established under this Agreement are unable to agree on any matter that is
subject to arbitration under Section 17.2.2 of this Agreement, then either Party
may give the other a written notice requesting arbitration to determine such
matter (a "BASEBALL ARBITRATION NOTICE"), in which case the matter shall be
determined by binding arbitration as follows ("BASEBALL ARBITRATION"):
(a) The Parties to the Baseball Arbitration shall be
Advancis and Par;
(b) The Parties shall jointly select a single arbitrator
within 15 days after the giving of the Baseball Arbitration
Notice.
(c) Within 30 days after the appointment of the arbitrator,
each Party shall submit a written report to the arbitrator and to
the other party, which report shall set forth the party's
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
37
- --------------------------------------------------------------------------------
determination of the matter in dispute (each, a "PROPOSAL"). Such
report may include such supporting documentation and related
calculations as the Party submitting the Proposal deems
appropriate.
(d) Except as otherwise specified in this Section 17.2.2,
the Baseball Arbitration shall be conducted in accordance with
Section 17.2.1 hereof.
(e) The arbitrator in any Baseball Arbitration shall have
only the authority to select the Proposal proposed by one of the
parties to the arbitration, based on which Proposal the
arbitrator believes constitutes the better estimate of the
Parties' intentions under this Agreement. The arbitrator shall
not have the authority to impose additional terms or a compromise
of the two Parties' Proposals.
(f) The parties agree that the decision of the arbitral
tribunal rendered in accordance with this Section 17.2.2 will be
final and binding. The Parties shall sign all papers and take all
actions that are required to obligate the Parties with respect to
and effectuate such decision and specific performance may be
ordered by any court of competent jurisdiction.
ARTICLE XVIII
MISCELLANEOUS
18.1 PUBLICITY. Neither Party shall originate any publicity, news
release or other public announcement, written or oral, relating to this
Agreement or the existence of a collaboration between the Parties, without the
prior written approval of the other Party except as otherwise permitted by this
Agreement or required, in the reasonable judgment of the disclosing party's
attorneys, by applicable law, including the Securities Act of 1933, as amended,
and the rules and regulations thereunder or as promulgated by an applicable
securities exchange governing body.
18.2 ASSIGNMENT. During the Term, neither this Agreement, nor any of
the Patent Rights licensed hereunder, nor any of the other rights or obligations
hereunder may be assigned by either Party without the prior written consent of
the other Party, which consent shall not be unreasonably withheld, except that
either Party may assign this Agreement and/or any or all of its Patent Rights
and/or other rights or obligations hereunder without such consent to an
Affiliate or to a party who acquires all or substantially all of the assets of
the assigning Party, whether through merger, acquisition, consolidation or
otherwise, provided in each instance that such acquiring Party agrees to be
subject to and bound by all of the terms and conditions of this Agreement. Any
purported assignment in contravention of this Section 18.2 shall be null and
void and of no effect.
18.3 GOVERNING LAW. This Agreement shall be governed by and interpreted
in accordance with the internal laws of the State of Delaware, without reference
to the conflicts of laws provisions thereof. Subject to Section 17.2: (a) each
Party irrevocably submits to the jurisdiction of any state or federal trial
court of competent subject matter jurisdiction in the State of Delaware for the
purposes of any suit, action or other proceeding arising out of this Agreement
or any transaction contemplated by this Agreement (and agrees not to commence
any action, suit or proceeding relating to this Agreement or any such
38
- --------------------------------------------------------------------------------
transaction, except in those courts), except for any patent infringement suit
brought against any third party by a Party hereto; (b) each Party further agrees
that service of any process, summons, notice or document in accordance with
Section 18.6 shall be effective service of process for any action, suit or
proceeding with respect to any matters to which it has submitted to jurisdiction
as set forth in the immediately preceding sentence; and (c) each Party
irrevocably and unconditionally waives any objection to the laying of venue of
any action, suit or proceeding arising out of this Agreement or the transactions
contemplated by this Agreement in any state or federal trial court of competent
jurisdiction in the State of Delaware, and further irrevocably and
unconditionally waives and agrees not to plead or claim in any such action, suit
or proceeding brought in any such court that such action, suit or proceeding has
been brought in an inconvenient forum. The rights and obligations of the Parties
under this Agreement shall not be governed by the provisions of the U.N.
Convention on Contracts for the International Sale of Goods.
18.4 FORCE MAJEURE. In the event that either Party fails to perform any
of its obligations under this Agreement (other than an obligation to pay money)
due to any act of God, fire, casualty, flood, war, strike, lockout, failure of
public utilities, injunction, act of a governmental authority (including
enactment of any governmental law, order or regulation permanently or
temporarily prohibiting or reducing the level of research, development or
production work hereunder or the manufacture, use or sale of the Products),
epidemic, destruction of production facilities, riot, insurrection, inability to
procure or use materials, labor, equipment, transportation or energy in
quantities sufficient to meet experimentation or manufacturing needs, or any
other cause beyond the reasonable control of the Party invoking this Section
18.4, provided, in each case, that such Party shall have used Commercially
Reasonable Efforts to avoid such failure, then such Party shall promptly give
written notice of such occurrence to the other Party, and thereupon the affected
Party's performance shall be excused and the time for performance shall be
extended for the period of delay or inability to perform due to such occurrence.
18.5 WAIVER. The waiver by either Party of a breach or a default of any
provision of this Agreement by the other Party shall not be construed as a
waiver of any succeeding breach of the same or any other provision, nor shall
any delay or omission on the part of either Party to exercise or avail itself of
any right, power or privilege that it has or may have hereunder operate as a
waiver of any right, power or privilege by such Party.
18.6 NOTICES. Any and all notices or other communications made or given
pursuant to this Agreement shall be in writing and shall be delivered (i) by
express overnight [or two-day international] courier service, (ii) by certified
or registered mail, return receipt requested, or (iii) by confirmed facsimile or
other electronic transmission (with confirming copy to follow by express
overnight courier service):
(a) if to Advancis, at 20425 Seneca Meadows Parkway, Germantown,
Maryland 20876, or at such other address or addresses as may be
furnished in writing by Advancis to Par, Attention: Kevin S. Sly,
Senior Vice President and Chief Business Officer, with copies to: Piper
Rudnick LLP, 6225 Smith Avenue, Baltimore, Maryland 21209 (Fax
202-580-3001) Attn: Howard S. Schwartz, Esq.
39
- --------------------------------------------------------------------------------
(b) if to Par, at 300 Tice Boulevard, Woodcliff, New Jersey
07677, Attention: Paul V. Campanelli, Vice President, Business
Development, or at such other address or addresses as may be furnished
in writing by Par to Advancis, with copies to: Par's General Counsel at
the same address and to Frommer Lawrence & Haug, 745 Fifth Avenue, New
York, New York 10151 (Fax 212-588-0800) Attn: Arthur Hoag, Esq.
Notices provided in accordance with this Section 18.6 shall be deemed
delivered upon receipt of the notice by the Party being sent the notice.
18.7 NO AGENCY. Nothing herein shall be deemed to constitute either
Party as the agent or representative of the other Party, or both Parties as
joint venturers or partners for any purpose. Advancis shall be an independent
contractor, not an employee or partner of Par, and the manner in which Advancis
performs its obligations under this Agreement shall be within Advancis's sole
discretion. Par shall be an independent contractor, not an employee or partner
of Advancis, and the manner in which Par performs its obligations under this
Agreement shall be within Par's sole discretion (subject to Par's compliance
with its obligations under this Agreement). Neither Party shall be responsible
for the acts or omissions of the other Party, and neither Party shall have
authority to speak for, represent or bind the other Party in any way without
prior written authority from the other Party.
18.8 ENTIRE AGREEMENT. This Agreement and the Exhibits and Schedules
attached hereto (which Exhibits and Schedules are deemed to be a part of this
Agreement for all purposes) contain the full understanding of the Parties with
respect to the subject matter hereof and supersede all prior understandings and
writings relating thereto. No waiver, alteration or modification of any of the
provisions hereof shall be binding unless made in writing and signed on behalf
of the Parties by their respective officers thereunto duly authorized.
18.9 HEADINGS; INTERPRETATION. The section headings contained in this
Agreement are for convenience of reference only, do not form a part of this
Agreement and shall not affect in any way the meaning or interpretation of this
Agreement. Whenever the context may require, any pronoun shall include the
corresponding masculine, feminine and neuter forms. The words "include,"
"includes" and "including" shall be deemed to be followed by the phrase "but not
limited to." All references herein to Articles, Sections and Exhibits shall be
deemed references to Articles and Sections of, and Exhibits to, this Agreement
unless the context shall otherwise require. All Exhibits and Schedules attached
to this Agreement shall be deemed incorporated herein by reference as if fully
set forth herein. Words such as "herein," "hereof," "hereto," "hereby" and
"hereunder" refer to this Agreement and to the Exhibits, taken as a whole.
Except as otherwise expressly provided herein: (a) any reference in this
Agreement to any agreement shall mean such agreement as amended, restated,
supplemented or otherwise modified from time to time; and (b) any reference in
this Agreement to any law shall include corresponding provisions of any
successor law and any regulations and rules promulgated pursuant to such law or
such successor law.
18.10 SEVERABILITY. In the event that any provision of this Agreement
is held by a court of competent jurisdiction to be unenforceable because it is
invalid or in conflict with any law of any relevant jurisdiction, the validity
of the remaining provisions shall not be affected, and the rights and
40
- --------------------------------------------------------------------------------
obligations of the Parties shall be construed and enforced as if the Agreement
did not contain the particular provisions held to be unenforceable.
18.11 SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and
inure to the benefit of the Parties hereto and their permitted successors and
assigns.
18.12 COUNTERPARTS. This Agreement may be executed in any number of
counterparts (including signature by facsimile), each of which shall be deemed
an original but all of which together shall constitute one and the same
instrument.
18.13 EXPORT CONTROLS. Each Party acknowledges that it is subject to
United States laws and regulations controlling the export of technical data,
computer software, laboratory prototypes and other commodities (including the
Arms Export Control Act, as amended and the United States Department of Commerce
Export Administrations Regulations). The transfer of such items may require a
license from the cognizant agency of the United States Government and/or written
assurances by Par or Advancis that it shall not export data or commodities to
certain foreign countries without prior approval of such agency. Neither Party
makes any representation as to whether any such license will be required or, if
required, whether it will be issued.
18.14 FURTHER ASSURANCES. Each Party hereby agrees, without further
consideration, to execute and deliver such documents and take such other actions
as the other Party may reasonably request to carry out the provisions hereof and
further the Collaboration.
41
- --------------------------------------------------------------------------------
EXECUTION
IN WITNESS WHEREOF, the Parties hereto have caused this Development and
Commercialization Agreement to be executed as a sealed instrument in their names
by their properly and duly authorized officers or representatives as of the date
first above written.
ADVANCIS PHARMACEUTICAL CORPORATION
By: /s/ Edward M. Rudnic
----------------------------
Print Name: Edward M. Rudnic
----------------------------
Title: Chairman & CEO
----------------------------
PAR PHARMACEUTICAL, INC.
By: /s/ Scott Tarriff
----------------------------
Print Name: Scott Tarriff
----------------------------
Title: President & CEO
----------------------------
42
- --------------------------------------------------------------------------------
EXHIBIT A
EXCLUSION FROM PRODUCTS
Any formulation comprising a Compound with a pharmacokinetic profile that (i)
[***].
As used herein, [***].
The contents of this Exhibit A are hereby incorporated into the Agreement and
are governed by the terms and conditions of the Agreement.
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
43
- --------------------------------------------------------------------------------
EXHIBIT B
FINANCIAL PLANNING SCHEDULE
This Exhibit B covers financial planning, accounting policies and procedures to
be followed in determining Development Costs and Operating Profits and related
issues regarding sharing and allocation of revenue and expenses pursuant to the
Agreement.
For purposes of this Exhibit B only, the consolidated accounting of operations
for the collaboration of the Parties under the Agreement shall be referred to as
the "COLLABORATION." The Collaboration is not a legal entity, pass through or
otherwise, for financial accounting or income tax reporting purposes, and has
been defined for identification purposes only.
This Exhibit B also provides agreed upon definitions of financial, accounting
and related terms applicable to the Parties for purposes of the Agreement. All
capitalized terms used herein without definition shall have the meanings
ascribed thereto in the Agreement, unless otherwise expressly provided herein.
B.1 DEFINITIONS.
B.1.1 "DEVELOPMENT COSTS" means all direct and indirect costs and
expenses incurred by Advancis pursuant to the budget set forth in the
Development Program, which may include (a) costs associated with designing,
planning and conducting Phase III Studies for the Products and all subsequent
clinical testing and trials, including in vitro and in vivo models, and (b)
costs in connection with seeking and obtaining Regulatory Approval, including
all FDA filing fees, (c) internal costs of Advancis personnel for salaries and
other compensation that are related to the fulfillment of the Development
Program paid by Advancis to its FTE's working on the Development Program,
calculated by multiplying the number of FTE's utilized for such purpose by the
FTE Rate, (d) payments made to Third Parties that are authorized by the
Development Plan, (e) materials and supplies, and (f) license or acquisition
fees and other costs and expenses associated with Advancis's obtaining from a
third party any trademarks, tradenames, logos, trade dress or similar
intellectual property rights licensed or acquired by Advancis after the
Effective Date for use in connection with the Commercialization of the Product.
B.1.2 "FTE" means a full time equivalent employee (i.e., one
fully-committed or multiple partially-committed employees aggregating to one
full-time employee) employed by a Party and assigned to perform specified work,
with such commitment of time and effort to constitute one employee performing
such work on a full-time basis, which for purposes hereof shall be [***] per
year.
B.1.3 "FTE RATE" means [***] per hour worked per FTE, which is the
equivalent of [***] per year per full-time FTE. The FTE Rate will change each
year in accordance with the annual percentage change in the Consumer Price Index
(U.S. Bureau of Labor Statistics for all urban consumers, U.S. city average-all
items).
B.1.4 "MANUFACTURING COSTS" means, with respect to any sale of
Products, the actual, out-of-pocket expense for obtaining such Products from the
manufacturer thereof, including costs of raw materials, equipment, packaging,
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
44
- --------------------------------------------------------------------------------
labeling, packing, shipping, storage, and other fixed costs, in each case
whether such amounts are payable directly to the manufacturer or to a third
party or to Advancis. Manufacturing Costs do not include Collaboration Payments,
if any, included in the price for Product.
B.1.5 "NET SALES OF PRODUCTS" means the actual invoiced gross sales of
Products to Third Parties by Par, its Affiliates and their Marketing
Distributors, as recorded by Par in accordance with generally accepted
accounting principals, less the following: (i) usual and customary allowances or
credits to such third parties for spoiled, damaged, rejected, recalled, outdated
and returned Products; (ii) freight, transportation, warehousing, storage,
postage and insurance charges to the extent separately identified on an invoice;
(iii) the amounts of trade, quantity and cash discounts actually allowed, to the
extent such trade, quantity and cash discounts are specifically allowed on
account of the purchase of such Products; (iv) sales taxes, excise taxes, use
taxes, value added taxes and import/export duties actually due or incurred or
allowed in connection with the sales of Products to any third party to the
extent separately identified on an invoice; (v) usual and customary allowances,
adjustments, reimbursements, discounts, chargebacks and rebates granted to third
parties, including rebates given to health care organizations or other third
parties, whether during the actual period or not; and (vi) usual and customary
allowances for doubtful accounts and actual chargeoffs for bad debt. "NET SALES
OF PRODUCTS" excludes any amounts invoiced or received in connection with any
transfers of a Product between Par and its Affiliates prior to final disposition
to third party customers but only where Products are to be resold to a third
party. "Net Sales of Products" also excludes transfers of Products made or used
for tests or development purposes, or distributed as donations or Samples and
for which no payment is received by Par or its Affiliates or sublicensees. In
the event that Par or its Affiliate or sublicensee, as the case may be, sells,
transfers or disposes of any Product for consideration, in whole or in part,
other than cash, the gross amount used for calculating Net Sales of Products for
such Product shall be deemed to be the standard invoice price then being
invoiced in arm's length transactions with similar customers. In the event that
Par sells a Product as part of a bundle or group sale with other products not
covered by the Agreement, and provides a discount, allowance or rebate to the
purchaser of such products based on the invoiced prices for all products sold,
such discount must be allocated pro rata based on average wholesale prices
across allsuch products and may not be applied disproportionately to the Product
sold as part of such bundle.
B.1.6 "OPERATING PROFITS" means, with respect to the sale of any
Product, the difference between Net Sales of Products and Manufacturing Costs
for such Product.
B.1.7 "PREMARKETING COSTS" means all direct and indirect costs and
expenses incurred by the Parties in connection with planning and implementing
the Premarketing Program but only to the extent authorized by the then-current
Commercialization Plan or otherwise agreed by written agreement of both Parties.
Premarketing Costs do not include Development Costs and/or Product Sales Force
Costs.
B.1.9 "PRODUCT SALES FORCE COSTS" means, with respect to each Party,
all costs associated with the Sales Representatives of such Party who are
conducting Details, including costs associated with salaries, bonus and similar
compensation payable to such Sales Representatives, employee benefits,
out-of-pocket expenses payable by the Party in connection with such Details, and
45
- --------------------------------------------------------------------------------
the like. Product Sales Force Costs shall not constitute Premarketing Costs or
Promotion Costs.
B.1.10 "PROMOTION COSTS" means, with respect to each Party, direct and
indirect costs and expenses (excluding Product Sales Force Costs) incurred by a
Party in connection with the Promotion of Products in the Territory pursuant to
and as authorized by the Commercialization Plans. Specific categories of
expenses constituting Promotion Costs shall be determined from time to time by
the Finance Subcommittee upon consultation with the Sales and Marketing
Subcommittee.
B.2 PRINCIPLES OF REPORTING.
The presentation of results of operations of the Parties in the Territory will
be based on each Party's respective financial information presented separately
and on a consolidated basis in a reporting format determined by the Finance
Subcommittee.
It is the intention of the Parties that the interpretation of these definitions
will be consistent with generally accepted accounting principles ("GAAP") in the
U.S.
If necessary, a Party will make the appropriate adjustments to the financial
information it supplies under the Agreement to conform to the format of
reporting results of operations determined by the Finance Subcommittee. Without
limiting the foregoing, prior to the time that Gross Sales are obtained, the
Parties may omit any line items related to sales and the support of sales, and
the costs thereof, from their respective financial reporting and report only
those items relevant to the payment of Development Costs.
B.3 FREQUENCY OF REPORTING.
Reporting by each Party for Collaboration revenues and expenses will be
performed as determined by the Finance Subcommittee.
Reports of actual results compared to budget will be made to the Finance
Subcommittee on a quarterly basis. After approval by the Finance Subcommittee as
to amounts, the Finance Subcommittee will forward the report to the Executive
Committee for its approval.
The Finance Subcommittee will be responsible for the preparation of consolidated
reporting of the Collaboration (including Development Costs and any Operating
Profit). Par will provide the Finance Subcommittee within thirty (30) days of
quarter end a statement showing the consolidated results and calculations of the
Operating Profit sharing (or calculation of expenses to be shared) in a format
determined by the Finance Subcommittee.
Par shall record sales in the U.S.
The Finance Subcommittee will meet as appropriate but at least quarterly to
review and approve the following: Development Costs (review only); actual
results; forecasts; budgets; inventory levels; Sales Returns and Allowances; and
other financial matters, including each Party's methodologies for charging costs
to the Collaboration, for determination of actuals, forecasts, budgets and long
range plans and the results of applying such methodologies.
46
- --------------------------------------------------------------------------------
B.4 COMMERCIALIZATION PLAN BUDGETS.
Budgets will be prepared annually with respect to each Draft Plan and
Commercialization Plan. Responsibility for such budgets will rest with the Sales
and Marketing Subcommittee, which will develop such budgets, with the assistance
of the Finance Subcommittee, subject to final approval by the Executive
Committee.
Commercialization Plan budgets will be supplemented with detailed business plans
for Product introductions, sales and Promotion efforts as determined by the
Finance Subcommittee. Budgets, once approved by the Executive Committee, can
only be changed with the approval of the Executive Committee.
The Finance Subcommittee, with the assistance of the Sales and Marketing
Subcommittee, will be responsible for identifying, analyzing and reporting all
significant line item budget variances and all overall, total budget variances
to the Executive Committee. Only the Executive Committee may approve materially
unfavorable line item budget variations, as defined by the Finance Subcommittee,
and all overall, total budget variations, chargeable to the Collaboration during
the course of the year.
Each Party shall be responsible for its own Product Sales Force Costs.
B.5 AUDITS AND REPORTS.
B.5.1 AUDIT. Par shall keep full, true and accurate books of account
containing all particulars as shall be pertinent for the purpose of showing any
Collaboration Payments and any other amounts due to Advancis from Par under the
Agreement. Such books of account shall be kept at Par's principal place of
business. Such books and the supporting data shall be open, at all reasonable
times and upon reasonable notice during the term of the Agreement, but no more
than four times per calendar year, and for three (3) years after the termination
of the Agreement or five (5) years following the end of the calendar year to
which they pertain, whichever is shorter, to the inspection of Advancis and its
authorized agents (including a certified public accounting firm selected by
Advancis), for the purpose of verifying Collaboration Payment reports provided
below and compliance in other respects with the Agreement. In the event that any
such inspection reveals a deficiency in excess of five percent (5%) of the
reported Collaboration Payments for the period covered by the inspection, Par
shall promptly pay Advancis (i) the deficiency, plus interest (at the rate
payable for overdue payment items pursuant to Section B.5.3) and (ii) the full
costs of such inspection. Otherwise, Advancis shall pay the full cost of such
inspection.
B.5.2 QUARTERLY REPORTS OF COLLABORATION PAYMENTS. Within thirty (30)
days after the end of the calendar quarters ending March 31, June 30 and
September 30 of each year and within forty-five (45) days after the end of the
calendar quarter ending December 31 of each year, Par shall deliver to Advancis,
at its principal place of business specified in the Agreement or at such other
address as Advancis shall, from time to time, specify to Par in writing, true
and accurate reports, certified by an authorized executive officer of Par,
giving such particulars of the business conducted by Par during the preceding
three-month period under the Agreement as shall be pertinent to a Collaboration
47
- --------------------------------------------------------------------------------
Payment accounting hereunder, regardless of whether any Collaboration Payments
are then due and owing to Advancis by Par.
B.5.3 OVERDUE PAYMENTS. Except to the extent provided otherwise in the
Agreement, the payment of Development Costs and Collaboration Payments shall, if
overdue, bear interest until payment at a per annum rate equal to one and a half
percent (1-1/2%) above the prime rate published in The Wall Street Journal on
the due date, not to exceed the maximum permitted by law, provided, however that
the payment of such interest shall not preclude Advancis from exercising any
other rights or remedies it may have as a consequence of the lateness of any
Collaboration Payment or other payment due hereunder.
B.5.4 ADDITIONAL INFORMATION. Par shall furnish Advancis, and Advancis
shall furnish Par, such additional information as the other Party may reasonably
request from time to time, to the extent that such information is reasonably
available, to ascertain the amount of Collaboration Payments and any other
amounts due Advancis under the Agreement.
B.6 SHARING PREMARKETING COSTS AND PROMOTION COSTS.
The Parties shall share equally in the Premarketing Costs and Promotion Costs
under the Commercialization Plans and the Agreement. Balancing payments between
the Parties for purposes of the sharing of Premarketing Costs and Promotion
Costs under the Agreement will be approved by the Finance Subcommittee. Within
thirty (30) days after the end of each calendar quarter, there shall be
reconciliation of the Premarketing Costs and Promotion Costs which are to be
shared and which are incurred during that quarter by the Parties, with a payment
by one Party to the other to the extent necessary so that each Party bears
one-half of Premarketing Costs and Promotion Costs. In the event any payment is
made after thirty (30)days after the end of a calendar quarter, the paying Party
shall increase the amount otherwise due and payable by adding interest thereon,
computed at the rate specified in Section B.5.3.
B.7 RESPONSIBILITY FOR REPORTING.
The responsibility for the consolidated reporting of the Collaboration to the
Finance Subcommittee shall be with Par in close cooperation with Advancis. Such
consolidated reports shall, after adjustments, if any, approved by the Finance
Subcommittee and the Executive Committee, be the basis for Collaboration
accounting and determining of payments to the Parties. Par shall provide the
Finance Subcommittee with a Collaboration consolidated reporting and its
proposed calculation of payments to the Parties no later than 45 days after the
end of each Quarter. Advancis shall provide Par with financial statements for
their Commercialization activities in the Territory, prepared in accordance with
the terms contained in this Exhibit B, within thirty (30) days after the end of
each Quarter in order for Par to prepare the consolidated reports.
B.8 ACCOUNTING FOR DEVELOPMENT COSTS, MANUFACTURING COSTS AND PROMOTION COSTS.
The Finance Subcommittee shall establish policies and procedures pursuant to
which the Premarketing Costs, Development Costs, Manufacturing Costs and
Promotion Costs incurred by the Parties shall be determined. Each Party shall
report its costs in accordance with the accounting policies and procedures
48
- --------------------------------------------------------------------------------
established by the Finance Subcommittee and shall not seek reimbursement from
the Collaboration for any costs in excess of such amounts.
B.9 PAYMENTS TO ADVANCIS OUT OF OPERATING PROFITS.
B.9.1 PAYMENTS. Par shall pay to Advancis the Collaboration Payments
derived from the sale of Products in the Territory, in an amount equal to [***]
of Operating Profits allocable to such sales.
B.9.2 PAYMENT TERMS. Operating Profits shall be determined on a
calendar quarter by calendar quarter basis. Par shall pay Collaboration
Payments, if any, to Advancis for each calendar quarter within thirty (30) days
after the end of such calendar quarter in which Net Sales of Products by Par
occur, such payment to be made by wire transfer of immediately available funds,
in United States dollars, to an account designated in advance by Advancis. Each
payment of Collaboration Payments by Par shall be accompanied by a copy of a
calculation of the amount due and payable, including a statement as to all
material information relevant to such calculation, including a statement as to
Net Sales of Products and Manufacturing Costs, including all components thereof,
and shall be final, non-refundable and not subject to adjustment.
B.9.3 TAXES. Par shall be responsible for paying all taxes (including
any related interest or penalties), however designated, imposed as a result of
the payment of any Royalties, including any sales and value added taxes and any
tax which Par is required to withhold or deduct from payments to Advancis, and
the Collaboration Payments paid to Advancis shall not be reduced as a result of
the payment by Par of any such taxes.
B.9.4 REPAYMENT OF DEVELOPMENT COSTS TO ADVANCIS. Notwithstanding
anything to the contrary set forth above in this Section B.9 or elsewhere in the
Agreement, prior to the retention by Par of any of its [***] share of the
Operating Profits generated from the sale of Products, Advancis shall first be
paid out of such Par share of Operating Profits an amount equal to any
Development Funding Gap then outstanding, or, if less, the total amount of such
Par share of Operating Profits. Such payment shall be made at the same time as
corresponding Collaboration Payments are made to Advancis.
B.10 PAYMENT OF DEVELOPMENT COSTS.
Development Costs shall be paid by Par as follows:
B.10.1 Par shall pay the Development Costs to Advancis in periodic
payments as follows:
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
49
- --------------------------------------------------------------------------------
PAYABLE ON OR BEFORE INSTALLMENT AMOUNT
-------------------- --------------------------
[***] [***]
[***] [***]
[***] [***]
[***] [***]
[***] [***]
[***] [***]
Total: $28,000, 00
B.11 START OF OPERATIONS AND EFFECTIVE ACCOUNTING DATE TERMINATION.
Operation of the Collaboration will be deemed to have commenced as of the
Effective Date.
For reporting and accounting purposes with respect to the Collaboration, the
effective termination date of the Agreement with regard to the last Detailing
year in the Territory will be the nearest month end to which such termination
takes place.
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
50
- --------------------------------------------------------------------------------
EXHIBIT C
COMMERCIALIZATION PARAMETERS AND DETAILING SCHEDULE
This Exhibit C covers Detailing and Promotional activities to be undertaken by
the Parties in connection with the Commercialization of the Products pursuant to
the Agreement.
This Exhibit C provides agreed upon definitions of terms applicable to the
Parties' Detailing, Promotional, and related Commercialization efforts under the
Agreement. All capitalized terms used herein without definition shall have the
meanings ascribed thereto in the Agreement, unless otherwise expressly provided
herein.
DEFINITIONS
C.1.1 "DETAIL" means a face-to-face meeting of a Sales Representative
with a medical professional having prescribing authority, during which meeting
scientific and/or medical information about the Products is discussed for the
purpose of encouraging sale of the Products. A Detail does not include a
reminder or Sample drop. Details shall be measured by each Party's internal
recording of such activity; provided that, such measurement shall be on the same
basis as the recording Party's measurement for its representatives that are
comparable to Sales Representatives with respect to detailing of such recording
Party's other products, consistently applied throughout the Term. When used as a
verb, the term "DETAILING" means to engage in the activity of a Detail.
C.1.2 "DETAILING PRIORITIES" means, with respect to each Party, the
priority position in which the Parties' Sales Representatives are required to
Detail the respective Products to a particular Targeted Prescriber, as compared
with other products being detailed by such Party. The Products shall be Detailed
only in the first Detail position, with at least [***] of the Detail time
devoted to the Products.
C.1.3 "DETAILING REQUIREMENTS" means the number of Details, Detailing
Priorities, and other aspects of Detailing directed to Targeted Prescribers
required of each Party in a given measurement period during the Term, as set
forth in the Commercialization Plan.
C.1.4 "PRODUCT SALES FORCE" means, with respect to each Party, a sales
and marketing force consisting of an appropriate number of trained and
experienced Sales Representatives capable of fulfilling all requirements of such
Party under the then-current Commercialization Plan, including compliance with
all Detailing Requirements during the respective measurement periods thereof.
C.1.5 "PROMOTE" means those activities other than Detailing that are
undertaken by a Party in order to encourage sales of Products, including journal
advertising, direct mail programs, direct-to-consumer advertising, convention
exhibits and other forms of advertising and promotion.
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
51
- --------------------------------------------------------------------------------
C.1.6 "SALES REPRESENTATIVE" means an individual who engages in
Detailing and similar sales efforts in the United States with respect to the
Products on a full-time basis.
C.1.7 "TARGETED PRESCRIBERS" means the set of physicians or other
authorized prescribers that the Parties expect to include in the
Commercialization Plans as the principal focus of their Commercialization
efforts.
The Parties hereby agree to the following commercial objectives, which shall be
reflected in the Commercialization Plans:
C.2.1 Secure [***] share of prescriptions in the amoxicillin market
segment
C2.2 Deliver not less than [***] Details to Targeted Prescribers of
amoxicillin, in the first twelve-month period following approval.
C2.3 Establish category leadership in journal advertising and medical
education programs as measured by generally-accepted industry audits that track
Promotional spending
C.2.4 Deliver [***] Sample units to Targeted Prescribers
C.2.5 Achieve [***] brand awareness at launch among Targeted
Prescribers
C.2.6 Gain preferred formulary status at [***] of major managed care
organizations
C.2.7 Achieve [***] stocking levels at high volume retail pharmacies
C.2.8 Establish [***] Product citations in the medical literature prior
to launch
The Parties agree that the following strategies shall be incorporated into the
Commercialization Plans:
C.3.1 Data Dissemination Strategy. Leverage relationships developed
with experts in the field of anti-infectives to generate scientific hypothesis,
data, and publications that support the strategic goals of amoxicillin PULSYS.
C.3.2 Advocacy Strategy. Leveraging scientific evidence supporting
amoxicillin PULSYS, build external advocates for the product within the
scientific and medical community for the purpose of influencing prescribing
behavior, medical guideline development, and general perception of amoxicillin
PULSYS in the market place.
C.3.3 Managed Care Strategy. Secure broad formulary coverage by
building a sound clinical and economic case supporting access and coverage while
maximizing profitability.
C.3.4 Targeted Prescriber Detailing Strategy. Focused detailing effort
directed at high volume prescribers responsible for generating majority of
prescriptions generated in the aminopenicillin market.
C.3.5 Medical Education Strategy. Utilize scientific and clinical data
supporting amoxicillin PULSYS to create medical education programs and
opportunities for medical, scientific, and health care professionals.
C.3.6 Pharmacy Stocking Strategy. Build and leverage relationships with
the trade and specifically major chains and distributors to ensure forced
distribution of amoxicillin PULSYS product presentations to retail outlets at
launch. To the extent possible, create stocking incentive programs that secure
desired reach while maintaining profitability goals. Augment national accounts
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
52
- --------------------------------------------------------------------------------
efforts with mail and telemarketing initiatives designed to drive demand among
retail outlets.
C.3.7 Accelerated Adoption Strategy. Identify and target early adopters
and key opinion leaders for involvement in "early access" or "real world"
experience studies to accelerate their adoption of amoxicillin PULSYS.
C.3.8 Phase IIIB/IV Clinical Evidence Strategy. Engage leading
investigators in the anti-infective field in the design and execution of
additional phase IIIB/IV studies to support the commercial objectives of
amoxicillin PULSYS.
The Parties agree that matters relating to pre-Commercialization activities and
expenses on which the Parties do not agree shall be submitted to the Sales and
Marketing Subcommittee for review in accordance with Section 3.3.
53
- --------------------------------------------------------------------------------
EXHIBIT D
DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES FOR COUNTRIES
OUTSIDE OF THE UNITED STATES
Subject to the provisions of this Agreement, Advancis has appointed Par as its
sole distributor of the Products in the Territory. This Exhibit D covers
development and Commercialization activities and related issues with respect to
the parties' goals and efforts to Commercialize the Products outside of the
United States.
This Exhibit D also provides agreed upon definitions of financial, accounting
and related terms applicable to the Parties for purposes of the Agreement. All
capitalized terms used herein without definition shall have the meanings
ascribed thereto in the Agreement, unless otherwise expressly provided herein.
References in this Exhibit D to a "PARTY" or "PARTIES" shall be construed to
mean Advancis or Par.
D.1 DEFINITIONS.
D.1.1 "EX-U.S. COUNTRY" means a country in the Ex-U.S. Territory.
D.1.2 "EX-U.S TERRITORY" means the countries in the Territory that are
not the United States and its possessions as of the Effective Date, as the same
may be changed in accordance with the provisions of this Exhibit D.
D.1.3 "EX-U.S. REGULATORY AUTHORITY" means any court, tribunal,
arbitrator, agency, commission, official or other instrumentality of any
federal, state, county, city or other political subdivision, that performs a
function for such political subdivision similar to the function performed by the
FDA for the United States with regard to the approval, licensing, registration
or authorization to test, manufacture, promote, market, distribute, use, store,
import, transport or sell a product in the applicable territory or political
subdivisions, or with respect to the approval of pricing or reimbursement for
such product.
D.1.4 "MAA" or "MARKETING APPROVAL APPLICATION" means a marketing
authorization application (including or comparable to an NDA), including all
supporting documentation and data submitted for such application to be accepted
for review or approval, filed with the requisite Ex-U.S. Regulatory Authority of
any Ex-U.S. country, and requesting approval for Commercialization of Products
for a particular indication in such country.
D.1.5 "MAA APPROVAL" means, with respect to any Ex-U.S. country,
approval by the applicable Ex-U.S. Regulatory Authority in such country of an
MAA filed in such country, permitting Products to be marketed in that country
for the indication(s) for which approval is sought, including, if applicable,
approval of pricing or reimbursement.
54
- --------------------------------------------------------------------------------
D.2 EX-U.S. PLANNING SUBCOMMITTEE.
D.2.1 Within [***] after the Effective Date, the Parties shall
establish a Subcommittee (the "EX-U.S. PLANNING Subcommittee") with
responsibility for identifying priorities relating to the development, product
selection, regulatory approval and Commercialization of Products in the Ex-U.S.
Countries, on a country by country basis and performing such other duties as may
be assigned under this Agreement or as may be delegated to the Ex-U.S. Planning
Subcommittee by the Executive Committee; provided that nothing in this Section
F.2.1 shall limit the rights or obligations of the Parties in this Agreement.
D.2.2 Each Party shall appoint two designees to the Ex-U.S. Planning
Subcommittee, each of whom shall have expertise and experience in the areas of
development, regulatory approval, marketing, Promotion, advertising and sales.
Either Party may replace any or all of its designees on the Ex-U.S. Planning
Subcommittee at any time upon written notice to the other Party, and any member
of the Ex-U.S. Planning Subcommittee may designate a suitable proxy to perform
the functions of that member at any time. In addition, the Ex-U.S. Planning
Subcommittee shall seek to act with the unanimous consent of the members of the
Ex-U.S. Planning Subcommittee. In the event that the Ex-U.S. Planning
Subcommittee members do not reach consensus with respect to a matter that is
within the purview of the Ex-U.S. Planning Subcommittee, the Ex-U.S. Planning
Subcommittee designees of each Party shall collectively have one vote for
purposes of decision-making hereunder with respect to such matters, with
decisions made by unanimous vote. If the votes of the Ex-U.S. Planning
Subcommittee are split on any matter, such matter shall be referred (by way of
the Alliance Managers) to the Executive Committee for decision. Any matter that
is not decided by the unanimous consent of all members of the Executive
Committee shall be subject to resolution by the chief executive officers of the
Parties pursuant to Section 17.1 and, thereafter, by arbitration in accordance
with Section 17.2.2.
D.3 DEVELOPMENT AND COMMERCIALIZATION PLANS.
D.3.1 The Ex-U.S. Planning Subcommittee shall work together in good
faith after the [***] of the Effective Date to commence the negotiation and
formulation of a detailed plan and budget for the development and
Commercialization of the Products in each country in the Ex-U.S. Territory (with
respect to each such country, the "D&C PLAN"). Any country for which the Ex-U.S.
Planning Subcommittee does not prepare a preliminary D&C Plan in accordance with
the provisions of this Exhibit D shall, as of the [***] of the Effective Date,
no longer be part of the Ex-U.S. Territory; provided that such period shall be
tolled in the event of a bona fide dispute between the Parties with respect to a
proposed D&C Plan for any Ex-U.S. Country that has been submitted to the
Executive Committee (or thereafter to arbitration pursuant to Section 17.2.2)
for resolution.
D.3.2 The Ex-U.S. Planning Subcommittee shall submit a preliminary D&C
Plan to the Executive Committee for approval no later than the third anniversary
of the Effective Date. Upon receipt of such preliminary D&C Plan, the Executive
Committee shall negotiate in good faith and take such other steps as may be
necessary to adopt a final approved D&C Plan not later than [***] thereafter.
Changes to the approved D&C Plan may be made at any time and from time to time
upon prior written agreement of both Parties or prior approval of the Executive
Committee. Any country for which the Executive Committee does not approve a D&C
Plan in accordance with the provisions of this Exhibit D shall, as of the date
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
55
- --------------------------------------------------------------------------------
that is [***] after the [***] of the Effective Date, no longer be part of the
Ex-U.S. Territory; provided that such period shall be tolled in the event of a
bona fide dispute between the Parties with respect to a proposed D&C Plan for
any Ex-U.S. Country and such dispute is being resolved by the chief executive
officers of the Parties pursuant to Section 17.1 and, thereafter, by arbitration
in accordance with Section 17.2.2.
D.3.3 Each D&C Plan shall provide that: (a) Par shall be solely
responsible for all costs of development, including obtaining MAA Regulatory
Approval in the subject country; (b) Par shall have the sole right to book sales
of the Products in the subject country; (c) Advancis will own all MAA Approvals
in the subject country; (d) Advancis will be solely responsible for the
manufacturing of Products relating to the development and Commercialization of
the Products in the subject country; (e) the Parties will have co-marketing
rights in the subject country; and (f) the Parties shall be equally responsible
for costs of Commercialization of the Products in the subject country. By mutual
agreement of the Parties, any of the foregoing obligations may be assumed, in
whole or in part, by one or more third parties.
D.3.5 Advancis shall own in their entirety (a) all clinical data and
reports related to clinical trials for the Products, and (b) all MAAs and MAA
Approvals for Products.
D.4 EX-U.S. DEVELOPMENT AND SALES AND MARKETING.
D.4.1 Promptly after the approval by the Executive Committee of each
D&C Plan, each of the Development and Manufacturing Subcommittee and the Sales
and Marketing Subcommittee shall assume its respective role with regard to the
such functions in the subject Ex-U.S. Country.
D.4.2 The provisions of this Agreement shall apply to all Ex-U.S.
Country development, manufacturing, sales and marketing efforts, as adjusted by
the Parties through one or more appropriate written amendments to this
Agreement, which may be on a country-by-country basis.
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL
TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS AMENDED.
56
- --------------------------------------------------------------------------------